<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Signal Transduct Target Ther</journal-id><journal-id journal-id-type="iso-abbrev">Signal Transduct Target Ther</journal-id><journal-title-group><journal-title>Signal Transduction and Targeted Therapy</journal-title></journal-title-group><issn pub-type="ppub">2095-9907</issn><issn pub-type="epub">2059-3635</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7289715</article-id><article-id pub-id-type="publisher-id">190</article-id><article-id pub-id-type="doi">10.1038/s41392-020-0190-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Overview of lethal human coronaviruses</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Chen</surname><given-names>Bin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Tian</surname><given-names>Er-Kang</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>He</surname><given-names>Bin</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Lejin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Ruiying</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Shuangwen</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Xiang</surname><given-names>Qianrong</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhang</surname><given-names>Shu</given-names></name><address><email>zhangs@wchscu.cn</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>El Arnaout</surname><given-names>Toufic</given-names></name><address><email>Toufic.arnaout@kappacrystals.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Cheng</surname><given-names>Wei</given-names></name><address><email>chengwei669@scu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.412901.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 1770 1022</institution-id><institution>Division of Respiratory and Critical Care Medicine, State Key Laboratory of Biotherapy, </institution><institution>West China Hospital of Sichuan University, </institution></institution-wrap>Chengdu, 610041 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.13291.38</institution-id><institution-id institution-id-type="ISNI">0000 0001 0807 1581</institution-id><institution>State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, </institution><institution>Sichuan University, </institution></institution-wrap>Chengdu, 610041 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.13291.38</institution-id><institution-id institution-id-type="ISNI">0000 0001 0807 1581</institution-id><institution>Department of Emergency Medicine, West China Hospital, </institution><institution>Sichuan University, </institution></institution-wrap>Chengdu, 610041 China </aff><aff id="Aff4"><label>4</label>Kappa Crystals Ltd., Dublin, Ireland </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>6</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>6</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>5</volume><elocation-id>89</elocation-id><history><date date-type="received"><day>5</day><month>4</month><year>2020</year></date><date date-type="rev-recd"><day>11</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>12</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Coronavirus infections of multiple origins have spread to date worldwide, causing severe respiratory diseases. Seven coronaviruses that infect humans have been identified: HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV, MERS-CoV, and SARS-CoV-2. Among them, SARS-CoV and MERS-CoV caused outbreaks in 2002 and 2012, respectively. SARS-CoV-2 (COVID-19) is the most recently discovered. It has created a severe worldwide outbreak beginning in late 2019, leading to date to over 4 million cases globally. Viruses are genetically simple, yet highly diverse. However, the recent outbreaks of SARS-CoV and MERS-CoV, and the ongoing outbreak of SARS-CoV-2, indicate that there remains a long way to go to identify and develop specific therapeutic treatments. Only after gaining a better understanding of their pathogenic mechanisms can we minimize viral pandemics. This paper mainly focuses on SARS-CoV, MERS-CoV, and SARS-CoV-2. Here, recent studies are summarized and reviewed, with a focus on virus&#x02013;host interactions, vaccine-based and drug-targeted therapies, and the development of new approaches for clinical diagnosis and treatment.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Structural biology</kwd><kwd>Infectious diseases</kwd><kwd>Vaccines</kwd><kwd>Infection</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Coronaviruses are crown-like particles with spikes protruding from their surface. They are enveloped viruses with single-stranded, positive-sense RNA (+ssRNA) genomes of approximately 26&#x02013;32&#x02009;kb, which is currently the largest known genome size for an RNA virus.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> RNA viruses are divided into five branches.<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref></sup> Certain groups in a particular branch might be related to and/or share features with viruses classified in another branch. In Branch 1 are the leviviruses and eukaryotic relatives (e.g., mitoviruses, narnaviruses, ourmiaviruses); Branch 2 represents several +RNA virus families (of eukaryotes) (e.g., orders <italic>Picornavirales</italic> and <italic>Nidovirales</italic>, and the families <italic>Caliciviridae</italic>, <italic>Potyviridae</italic>, <italic>Astroviridae</italic>, and <italic>Solemoviridae</italic>) and several dsRNA viruses (e.g., partitiviruses and picobirnaviruses); In Branch 3 are certain +RNA viruses such as the supergroups of alphaviruses and offlaviviruses, the nodaviruses, tombusviruses, and many small and novel groups; In Branch 4 are dsRNA viruses such as the cystoviruses, reoviruses, and totiviruses; Branch 5 consists of &#x02212;RNA viruses.<sup><xref ref-type="bibr" rid="CR2">2</xref></sup> Coronaviruses were classified as most likely related to Branch 2, and belong to the order <italic>Nidovirales</italic>, and the family <italic>Coronaviridae</italic>. In 2018, the International Committee on Taxonomy of Viruses divided the <italic>Coronaviridae</italic> into the <italic>Orthocoronavirinae</italic> and <italic>Letovirinae</italic> subfamilies.</p><p id="Par3">According to their host targets, coronaviruses can also be divided into animal and human coronaviruses. Many diseases in domestic animals are related to animal coronaviruses, such as canine respiratory coronavirus, which causes respiratory disease in dogs.<sup><xref ref-type="bibr" rid="CR4">4</xref></sup> The highly pathogenic human coronaviruses belong to the subfamily <italic>Coronavirinae</italic> from the family <italic>Coronaviridae</italic>. The viruses in this subfamily group into four genera: <italic>Alphacoronavirus</italic>, <italic>Betacoronavirus</italic>, <italic>Gammacoronavirus</italic>, and <italic>Deltacoronavirus</italic>. The classic subgroup clusters are labeled 1a&#x02013;1b for the alphacoronaviruses and 2a&#x02013;2d for the betacoronaviruses. To date, including the recently discovered SARS-CoV-2, there are seven coronaviruses that infect humans. Human coronavirus (HCoV)-229E, HCoV-NL63, HCoV-OC43, or HCoV-HKU1 cause only the common cold,<sup><xref ref-type="bibr" rid="CR5">5</xref></sup> whereas the severe acute respiratory syndrome coronavirus (SARS-CoV) or the Middle East respiratory syndrome coronavirus (MERS-CoV) cause relatively high mortality and emerged in 2002<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> and 2012,<sup><xref ref-type="bibr" rid="CR7">7</xref></sup> respectively. Notably, SARS-CoV-2 is currently causing a worldwide epidemic. SARS-CoV and MERS-CoV belong to subgroups 2b and 2c of the betacoronaviruses, respectively,<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup> whereas SARS-CoV-2 is a new member of the betacoronaviruses distinct from SARS-CoV and MERS-CoV.<sup><xref ref-type="bibr" rid="CR9">9</xref></sup> Figure <xref rid="Fig1" ref-type="fig">1</xref> shows the phylogenetic tree of RNA viruses.<fig id="Fig1"><label>Fig. 1</label><caption><p>Phylogenetic tree of coronaviruses based on full-length genome sequences. All complete genome sequences of coronavirus were downloaded from the NCBI reference sequence database, RefSeq. The tree was constructed using maximum likelihood estimation (MLE) by MEGA X, with Clustal Omega as the multiple sequence alignment method, and 1000 bootstrap replicates. Only bootstraps &#x02265;50% values are shown. The seven known human-infecting coronaviruses are indicated with a red star</p></caption><graphic xlink:href="41392_2020_190_Fig1_HTML" id="d30e433"/></fig></p><p id="Par4">The estimated mutation rates of coronaviruses (CoVs) are moderate to high compared to those of other ssRNA viruses.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> There are two gene loci that are sites of variation in SARS-CoV. One of these sites is located in the spike (S) protein gene. The second major site of variation is the accessory gene open reading frame ORF8. In MERS-CoV, the major sites of variation are located in the S, ORF4b, and ORF3 genes.<sup><xref ref-type="bibr" rid="CR2">2</xref></sup> The major differences in the sequence of the S gene of SARS-CoV-2 are three short insertions in the N-terminal domain and changes in four out of five of the key residues in the receptor-binding motif.<sup><xref ref-type="bibr" rid="CR9">9</xref></sup> The organizations of the genome and gene expression are similar for all coronaviruses. ORF1a/b, located at the 5&#x02032; end, encodes 16 nonstructural proteins (NSPs) (named NSP1&#x02013;NSP16); other ORFs at the 3&#x02032; end encode structural proteins, including the S, envelope (E), membrane (M), and nucleocapsid (N) proteins.</p><p id="Par5">The mutations in SARS-CoV-2 have become a hot research topic. The surface proteins of SARS-CoV and BatCoV-RaTG13, the nearest potential bat precursors of SARS-CoV-2, have 76 and 97% sequence identity, respectively, to that of SARS-CoV-2.<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> Compared to that of SARS-CoV, the antigenic surface of SARS-CoV-2 is highly divergent compared to other CoVs. Since its outbreak began at the end of 2019, SARS-CoV-2 has acquired mutations throughout its genome, and there are already hundreds of virus strains distributed worldwide. According to GISAID.org, as of May 8, there were 16,004 full genome sequences available, and the S clade of the full genome tree contains the largest group of viruses, indicating that mutations in ORF8-L84S are most frequent. The temporal resolution assumes an average nucleotide substitution rate of 5&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;4</sup> substitutions per site per year. Based on these mutations, researchers found that SARS-CoV-2 can be divided into two subtypes. They reported that the SNPs at locations 8782 and 28,144 show strong linkage; the &#x0201c;CT&#x0201d; haplotype was defined as the &#x0201c;L&#x0201d; type because T28,144 encodes leucine, while the &#x0201c;TC&#x0201d; haplotype was defined as the &#x0201c;S&#x0201d; type because C28,144 encodes serine,<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> which is in accordance with another study that divided SARS-CoV-2 into two types.<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> The &#x0201c;L&#x0201d; type seems to be more prevalent and aggressive, but the &#x0201c;S&#x0201d; type may be ancestral, as sites 8782 and 28,144 were identical to the orthologous sites in the most closely related viruses.<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> Patients may be infected by either or both types.<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> From the GISAID update, compared with RaTG13, there are differences in the receptor-binding interface, which may have favored host switching. Data related to the sequence and mutations of SARS-CoV-2 are also available and continuously updated online through the China National Center for Bioinformation (CNCB) (<ext-link ext-link-type="uri" xlink:href="https://bigd.big.ac.cn/ncov">https://bigd.big.ac.cn/ncov</ext-link>).</p></sec><sec id="Sec2"><title>Lethal human coronaviruses</title><sec id="Sec3"><title>The history of SARS-CoV, MERS-CoV, and SARS-CoV-2</title><p id="Par6">The first case of SARS was discovered in Foshan, China, in November 2002.<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> Infections occurred through either direct or indirect contact with patients. By July 2003, SARS-CoV had spread to over 30 countries,<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> causing 8096 reported cases and 774 deaths. After that, no additional infections were detected, and the SARS pandemic was declared over. SARS-CoV was first isolated from Himalayan palm civets (HPCs) from a live-animal market in Guangdong, China.<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR14">14</xref></sup> Other animals, such as raccoon dogs (<italic>Nyctereutes procyonoides</italic>), along with human workers from the same market, also showed evidence of viral infection.<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> Multiple studies have demonstrated that the reservoirs of several coronaviruses, including SARS-CoV-like and MERS-CoV-like viruses, were bats.<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup> Although palm civets might have been intermediary hosts of SARS-CoV,<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> researchers often concluded there was no evidence that these animals were the ultimate sources of SARS-CoV, and the viruses cannot circulate directly in palm civets in the wild.<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> In 2003, Guan and Zheng&#x02019;s team investigated a live-animal retail market in Guangdong, focusing on recently captured wild animals and human consumption. The animals sampled included seven wild and one domestic animal species. They collected nasal and fecal samples with swabs and then used reverse transcription-polymerase chain reaction (RT-PCR) to test for viral nucleic acid from the N gene of the human SARS-CoV. The RT-PCR assay results showed that samples from four of six HPCs were positive; the other seven species (beaver, Chinese ferret-badger, Chinese hare, Chinese muntjac, domestic cat, hog-badger, and raccoon dog) sampled were negative.<sup><xref ref-type="bibr" rid="CR12">12</xref></sup></p><p id="Par7">MERS-CoV was first found in 2012 in a lung sample from a 60-year-old patient who died of respiratory failure in Jeddah, Saudi Arabia. On 15 September 2012, a similar type of virus named human coronavirus was isolated from a patient with severe respiratory infection. Cases have also been reported in other countries.<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> MERS has a 35% mortality rate, and since it emerged in the human population in June 2012, it has caused substantial morbidity and mortality.<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup> From 2012 until January 15, 2020, the total number of laboratory-confirmed MERS-CoV infection cases reported globally to the World Health Organization (WHO) was 2506, with 862 associated deaths, covering 27 countries (<ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/31-january-2020-mers-united-arab-emirates/en">www.who.int/csr/don/31-january-2020-mers-united-arab-emirates/en</ext-link>). Cases of MERS from other countries were linked to travel to the Middle East.<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup> MERS-CoV was identified from the saliva of a patient with acute pneumonia and renal failure in Jeddah (KSA). MERS-CoV can be detected in respiratory tract secretions, as well as in feces, serum, and urine.<sup><xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref></sup> In addition, it has been isolated from environmental objects such as bedsheets, bedrails, intravenous fluid hangers, and X-ray devices.<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> In the case of known camel infection, MERS-CoV was transmitted from a camel to a human, which was confirmed by RNA sequencing.<sup><xref ref-type="bibr" rid="CR26">26</xref></sup></p><p id="Par8">At the end of December 2019, the first clusters of patients with pneumonia caused by SARS-CoV-2 were reported in Wuhan, China.<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> The basic reproduction number of SARS-CoV-2 is approximately 2.2, indicating that each patient would on average spread the infection to 2.2 people.<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> Human-to-human transmission of SARS-CoV-2 occurred rapidly, and the atypical symptoms during the early stage may be a further disadvantage.<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> Moreover, human infection might have begun months prior to the official announcement of the outbreak.<sup><xref ref-type="bibr" rid="CR30">30</xref></sup></p><p id="Par9">To prevent further spread, stricter screening and surveillance are needed at travel hubs.<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> Early detection, diagnosis, and treatment are also effective measures to contain the epidemic.<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> Nonetheless, the fatality rate of SARS-CoV-2 is lower than that of SARS,<sup><xref ref-type="bibr" rid="CR33">33</xref></sup> with an estimated mortality risk of 2%.<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> SARS-CoV-2 was first isolated from clinical specimens using human airway epithelial cells and the Vero E6 and Huh-7 cell lines.<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> Approaches to assess virions include isolation from lower respiratory tract specimens<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> and artificially infected specific pathogen-free human airway epithelial cells.<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> Fluorescence quantitative PCR with primers designed according to specific sequences and serological testing aimed at IgG and IgM can be used to detect the virus.<sup><xref ref-type="bibr" rid="CR9">9</xref></sup></p><p id="Par10">SARS-CoV, MERS-CoV, and SARS-CoV-2 pose major challenges to global health, causing infections in large parts of the world. SARS-CoV was found in 30 countries and MERS-CoV in 27 countries, while SARS-CoV-2 was found in 213 countries by 8th May, 2020. Details on the pandemics caused by SARS-CoV-2 are shown in Box <xref rid="Sec4" ref-type="sec">1</xref>, highlighting the status of the coronavirus-caused diseases worldwide.</p></sec><sec id="Sec4"><boxed-text><label>Box 1 Epidemic information of COVID-19</label><p id="Par11">As of May 8, 2020, there are 1,654,345 confirmed cases and 152,179 deaths in the European region; 1,586,129 confirmed cases and 87,930 deaths in the region of the Americas; 237,323 confirmed cases and 8608 deaths in the Eastern Mediterranean region; 157,447 confirmed cases and 6394 deaths in the Western Pacific region; 86,294 confirmed cases and 3075 deaths in the South-East Asia region; 33,973 confirmed cases and 1202 deaths in the Africa region.<graphic position="anchor" xlink:href="41392_2020_190_Figa_HTML" id="MO1"/></p></boxed-text></sec><sec id="Sec5"><title>Epidemiological analysis and symptoms of SARS, MERS, and coronavirus disease 2019 (COVID-19)</title><p id="Par12">The clinical manifestations of SARS include hypoxia, cyanosis, high fever (above 38&#x02009;&#x000b0;C), accelerated breathing or respiratory distress syndrome, and shortness of breath. X-rays show changes to the lungs to varying degrees. The WHO case definition (2003) includes the following: (1) fever higher than 38&#x02009;&#x000b0;C or history of such in the past 2 days, (2) radiological evidence of new infiltrates consistent with pneumonia, (3) chills, cough, malaise, myalgia, or known history of exposure, and (4) positive test for SARS-CoV by one or more assays.<sup><xref ref-type="bibr" rid="CR37">37</xref></sup></p><p id="Par13">Similar to SARS-CoV infection, MERS-CoV infection manifests as a severe lower respiratory tract infection with extrapulmonary involvement and high fatality rates.<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> Symptomatic patients may present fever, chills, stiffness, myalgia, discomfort, cough, shortness of breath, and gastrointestinal symptoms of diarrhea, vomiting, and abdominal pain. Pneumonia is common, and severe infection with acute respiratory failure, renal failure, and shock is particularly frequent among older patients.<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> Previous studies have estimated that approximately 12.5&#x02013;25% of MERS-CoV infections may be asymptomatic.<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup> It must be noted that immunocompromised people are at high risk of MERS-CoV infection.<sup><xref ref-type="bibr" rid="CR21">21</xref></sup></p><p id="Par14">For COVID-19, fever, cough, myalgia, and fatigue are most commonly observed at illness onset; less commonly observed are sputum production, hemoptysis, and headache, among others.<sup><xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup> Similar to SARS and MERS, some patients develop acute respiratory distress syndrome (ARDS).<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> Around 81% of infected patients only develop mild symptoms, with mild pneumonia or no pneumonia. 14 and 5% are severe and critical status, respectively.<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> Patients requiring ICU care tend to be much older and are more likely to have underlying comorbidities, such as hypertension and diabetes.<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> Additionally, symptoms such as pharyngeal pain and anorexia are reported at higher rates among those admitted to the ICU than among non-ICU patients.<sup><xref ref-type="bibr" rid="CR29">29</xref></sup></p><p id="Par15">Histopathologically, symptoms such as diffuse alveolar damage (DAD), loss of cilia, squamous metaplasia, denudation of bronchial epithelia, and giant-cell infiltrate often occur in the lungs of patients with SARS. The number of macrophages increases prominently in the alveoli and the interstitium.<sup><xref ref-type="bibr" rid="CR41">41</xref></sup> According to the morphological changes, observed, most authors have subclassified lung lesions in SARS into two or three consecutive phases: an acute exudative inflammatory phase, a fibrous proliferative phase, and a final fibrotic stage, although there is considerable overlap in histological findings among these phases.<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> The main features of the first phase include extensive hyaline membrane formation, edema, alveolar hemorrhage, and fibrin exudation in alveolar spaces. The second phase includes widening of septae, pneumocyte hyperplasia, and organizing fibromyxoid and cellular exudates.<sup><xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR43">43</xref></sup> The third phase includes septal and alveolar fibrosis.<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> Several autopsies of SARS patients have demonstrated secondary bronchopneumonia, and the pathogens identified mainly consist of <italic>Staphylococcus aureus, Mucor sp., Aspergillus sp., Pseudomonas aeruginosa</italic>, and cytomegalovirus.<sup><xref ref-type="bibr" rid="CR43">43</xref></sup> SARS-CoV also greatly affects the immune system. For example, hemorrhagic necrosis is usually obvious in the lymph nodes and spleen.<sup><xref ref-type="bibr" rid="CR44">44</xref></sup> As described above, SARS-CoV attacks immune cells, especially T cells and macrophages, with approximately 50% of lymphocytes and 30% of monocytes in the circulation becoming infected.<sup><xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR45">45</xref></sup> Under the influence of the virus, the patient&#x02019;s germinal centers disappear, and both T and B lymphocytes are depleted. In the spleen, the white pulp shrinks, hemorrhage and necrosis occur in the red pulp, and the periarterial lymphatic sheaths decrease.<sup><xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup> With regard to the immune system, SARS-CoV can infect the lymphoid component of the intestine. For this reason, the patient&#x02019;s submucosal lymphoid tissue atrophies.<sup><xref ref-type="bibr" rid="CR47">47</xref></sup> SARS-CoV can also infect epithelial cells in the mucosa of the small and large intestines, and the digestive tract may undergo mild diffuse inflammation and atrophy of the submucosal lymphoid tissues.<sup><xref ref-type="bibr" rid="CR47">47</xref></sup> According to previous reports, symptoms in the liver include extensive hepatocyte mitosis, balloon degeneration of hepatocytes, mild to moderate lymphocytic infiltrates, fatty degeneration, and central lobular necrosis.<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> Additionally, apoptosis of liver cells has been confirmed in some cases.<sup><xref ref-type="bibr" rid="CR48">48</xref></sup> On autopsy, the kidneys of some SARS patients showed focal bleeding and acute tubular necrosis of different degrees. One of the major complications of ARDS is acute kidney injury.<sup><xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup> In many other cases, the features are nonspecific, including benign hypertensive nephrosclerosis and autolysis.<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> Moreover, researchers have detected viral particles and genome sequences in the cytoplasm of neurons of the hypothalamus and cortex in the brain,<sup><xref ref-type="bibr" rid="CR51">51</xref></sup> which suggests that the virus can cross the blood&#x02013;brain barrier and cause degeneration and necrosis of neurons, edema, extensive glial cell hyperplasia, and cellular infiltration.<sup><xref ref-type="bibr" rid="CR42">42</xref></sup></p><p id="Par16">Pneumocytes and epithelial syncytial cells are important targets of MERS-CoV. The lung tissue presents DAD. Severe peripheral vascular diseases, patchy cardiac fibrosis, and hepatic steatosis have also been found in other organs.<sup><xref ref-type="bibr" rid="CR52">52</xref></sup> Another symptom is bronchial submucosal gland necrosis.<sup><xref ref-type="bibr" rid="CR52">52</xref></sup> Renal biopsy may show acute tubulointerstitial nephritis and acute tubulosclerosis with protein casts.<sup><xref ref-type="bibr" rid="CR22">22</xref></sup></p><p id="Par17">In COVID-19 patients, a bilateral (sometimes unilateral) distribution of patchy shadows and ground glass opacity in the lungs is typical, based on CT scans.<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> Plasma concentrations of interleukins (ILs) 2, 7, and 10, granulocyte-colony stimulating factor, interferon(IFN)-&#x003b3;-inducible protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1&#x003b1;, and tumor necrosis factor &#x003b1; are increased in most dying patients.<sup><xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR53">53</xref></sup> In addition, neutrophilia related to cytokine storms induced by virus invasion, coagulation activation related to a sustained inflammatory response, and acute kidney injury related to the effects of the virus, hypoxia, and shock, may be involved in mortality.<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> Those who survive intensive care may experience long-term lung damage and fibrosis due to aberrant and excessive immune responses.<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> Moreover, researchers found that as SARS-CoV-2 spread and changed across generations, clinical symptoms started to differentiate those infected previously from those infected more recently. The initial symptoms are becoming more insidious, which indicates that the virus may gradually evolve into an influenza-like virus and lie dormant for longer in asymptomatic patients.<sup><xref ref-type="bibr" rid="CR54">54</xref></sup></p><p id="Par18">In conclusion, in terms of outbreak times, SARS-CoV was the earliest, followed by MERS-CoV, then SARS-CoV-2. To date, MERS-CoV has the longest duration of infection, and SARS-CoV-2 appears to be the most infectious. SARS-CoV, MERS-CoV, and SARS-CoV-2 infections have similar symptoms, including fever, cough, myalgia, and shortness of breath, among others. The common transmission methods and symptoms of the three coronavirus infection are shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref>.<fig id="Fig2"><label>Fig. 2</label><caption><p>Common transmission methods and symptoms of coronavirus infection. The main modes of transmission include droplet transmission, contact transmission, and fecal&#x02013;oral transmission. Fever, cough, fatigue, muscle soreness, and abdominal pain are common symptoms of the three coronavirus infections</p></caption><graphic xlink:href="41392_2020_190_Fig2_HTML" id="d30e822"/></fig></p></sec><sec id="Sec6"><title>Structural studies of SARS-CoV, MERS-CoV, and SARS-CoV-2</title><p id="Par19">SARS-CoV is a coronavirus with a diameter of approximately 100&#x02009;nm. Coronaviruses are the largest +ssRNA viruses and contain at least 14 ORFs,<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR55">55</xref></sup> among which five main ORFs encode the replicase (Rep), and the S, E, M, and N proteins.<sup><xref ref-type="bibr" rid="CR56">56</xref></sup> Similar to other coronaviruses, there is a wide array of spike proteins on the envelope of SARS-CoV that resemble a corona. With its unique RNA-dependent RNA polymerase (RdRp), SARS-CoV often switches template strands during replication. Thus, if a cell is infected with several coronaviruses, RNA recombination may occur. The N protein combines with viral RNA to form a nucleocapsid, which is involved in the replication of SARS-CoV and is the most abundant protein in virus-infected cells.<sup><xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR57">57</xref></sup> The M protein is a membrane glycoprotein that is involved in budding and envelope formation. The S protein of SARS-CoV is a type I transmembrane (TM) glycoprotein that is responsible for viral binding, fusion and entry into cells, as well as antibody induction.<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR58">58</xref></sup> The S protein contains a signal peptide (SP: amino acids 1&#x02013;12) and three domains called the extracellular domain (amino acids 13&#x02013;1193), the TM domain (amino acids 1194&#x02013;1215) and the intracellular region (amino acids 1216&#x02013;1255).<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> The extracellular domain consists of two subunits: S1 and S2. The fragment located in the middle region of the S1 subunit (amino acids 318&#x02013;510) is the angiotensin-converting enzyme 2 (ACE2) receptor-binding region. The S2 subunit comprises a fusion peptide (FP) and two x 7-valent element repeats (HR1 and HR2) that are responsible for fusion between the virus and the target cell membrane.<sup><xref ref-type="bibr" rid="CR58">58</xref></sup> Thus, the S protein may be key to develop a vaccine to generate antibodies and block virus binding and fusion in the coronaviruses (Fig. <xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Clustering of the spike protein of each coronavirus. Fifty-four spike protein sequences filtered from each coronavirus coding sequences were clustered using the CLANS (CLuster ANalysis of Sequences) program on the website of MPI Bioinformatics Toolkit. Each colored dot represents the spike protein sequence of each coronavirus. Dots in the same color mean they are of the same genus, and each line shows the similarity of two sequences, with darker lines indicating higher similarity (lower <italic>E</italic> values). The Coronaviridae family includes the following genera: Alphacoronavirus (colored in green); Betacoronavirus (red); Gammacoronavirus (orange), and Deltacoronavirus (blue). The indicated SARS-CoV, MERS-CoV, and SARS-CoV-2 belong to the genus of Betacoronavirus</p></caption><graphic xlink:href="41392_2020_190_Fig3_HTML" id="d30e876"/></fig></p><p id="Par20">The 3&#x02032; end of the SARS virus genome encodes 12 structural proteins and helper proteins, of which ORF3a, ORF6, ORF7a, and ORF7b have been proven to be viral structural proteins involved in the formation of viral particles. The 5&#x02032; end of the genome encodes 16 nonstructural proteins (NSPs), which are important for virus assembly, and may enable the design of small molecule drugs and/or vaccines.</p><p id="Par21">MERS-CoV belongs to lineage C of the genus <italic>Betacoronavirus</italic> (<italic>&#x003b2;</italic>CoV) in the family <italic>Coronaviridae</italic>, order <italic>Nidovirales</italic>, and it is the first lineage C CoV and the sixth CoV known to cause human infection. MERS-CoV is an enveloped +ssRNA virus similar to other CoVs, but the amino acid sequence homology between MERS-CoV and other known CoVs is less than 90%.<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> ORF1a and ORF1b located in the first two-thirds of the MERS-CoV genome are involved in virulence and encode NSPs (NSP1&#x02013;16). The remaining third of the genome encodes four structural proteins, the S, E, M, and N proteins, as well as five accessory proteins (ORF3, ORF4a, ORF4b, ORF5, and ORF8b).<sup><xref ref-type="bibr" rid="CR59">59</xref>&#x02013;<xref ref-type="bibr" rid="CR61">61</xref></sup> The flanking regions of the genome contain the 5&#x02032; and 3&#x02032; untranslated regions (UTRs).<sup><xref ref-type="bibr" rid="CR62">62</xref></sup> Most MERS-CoV proteins are found in the cytoplasm.<sup><xref ref-type="bibr" rid="CR63">63</xref></sup> To date, the NS4b protein and the ORF3a-encoded protein are the only known coronavirus proteins to be detected in the nucleus.<sup><xref ref-type="bibr" rid="CR64">64</xref></sup> NSP1 suppresses host gene expression in infected cells, and its RNA cleavage-inducing function promotes virus assembly/budding.<sup><xref ref-type="bibr" rid="CR65">65</xref></sup> NSP16 is a viral 2&#x02032;-<italic>O</italic>-methyltransferase (2&#x02032;-<italic>O</italic>-MTase) that encodes critical functions in immune modulation and infection, suggesting that NSP16 is a conserved universal candidate for rapid design of a live attenuated vaccine.<sup><xref ref-type="bibr" rid="CR66">66</xref></sup> ORF4a&#x02019;s protein can mask viral dsRNA to play a role in immune evasion, including type 1 IFN and protein kinase R-mediated antiviral stress responses.<sup><xref ref-type="bibr" rid="CR67">67</xref></sup> MERS-CoV NSP13 is a full-length coronavirus helicase that contains multiple domains, including an N-terminal Cys/His rich domain with three zinc atoms, a beta-barrel domain and a C-terminal superfamily (SF) 1 helicase (SF1) core with two RecA-like subdomains. This protein might interfere with the nonsense-mediated mRNA decay pathway to avoid degradation of viral RNA.<sup><xref ref-type="bibr" rid="CR68">68</xref></sup></p><p id="Par22">The MERS-CoV S protein can recognize dipeptidyl peptidase 4 (DPP4) on the cell surface, promoting the fusion of the viral envelope and the cell membrane. The MERS-CoV S protein, a 1353-amino acid type I TM glycoprotein located on the viral envelope surface, is composed of S1 and S2 subunits.<sup><xref ref-type="bibr" rid="CR69">69</xref></sup> The structure of the S protein consists of four parts: an SP located at the N terminus (amino acids 1&#x02013;12), an extracellular domain (amino acids 13&#x02013;1195), a TM domain (amino acids 1196&#x02013;1215), and an intracellular domain (amino acids 1216&#x02013;1255).<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> The S1 subunit contains two independent domains, an N-terminal domain (NTD, amino acids 18&#x02013;353)<sup><xref ref-type="bibr" rid="CR70">70</xref></sup> and a C-terminal domain (amino acids 367&#x02013;588), both of which may function as receptor-binding domains (RBDs);<sup><xref ref-type="bibr" rid="CR71">71</xref></sup> these domains serve as critical targets for the development of vaccines and therapeutics<sup><xref ref-type="bibr" rid="CR72">72</xref>,<xref ref-type="bibr" rid="CR73">73</xref></sup> and facilitate the involvement of the S1 subunit in cell receptor (DPP4) binding. The core structure of the MERS-CoV S protein RBD is a five-stranded antiparallel sheet with several short helices, in which three disulfide bonds stabilize the core by connecting C383 to C407, C425 to C478, and C437 to C585.<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR73">73</xref></sup> The accessory subdomain of the C-domain is a hypervariable region for receptor recognition and is called the receptor-binding motif (RBM). The accessory subdomains in SARS-CoV and MERS-CoV differ, resulting from divergent evolution and leading to the use of different receptors.<sup><xref ref-type="bibr" rid="CR71">71</xref></sup> DPP4 consists of an N-terminal hydrolase and a C-terminal &#x003b2;-propeller domain composed of eight lancets<sup><xref ref-type="bibr" rid="CR74">74</xref></sup> and the RBD. The S2 subunit of MERS-CoV contains an FP (residues 943&#x02013;982), an HR1 domain (residues 984&#x02013;1104), an HR2 domain (residues 1246&#x02013;1295), a TM domain (residues 1296&#x02013;1317), and an intracellular domain (residues 1318&#x02013;1353).<sup><xref ref-type="bibr" rid="CR69">69</xref></sup> The S2 subunit is responsible for fusion between the virus and the target cell membrane. After the S1 subunit binds to DPP4, the S2 subunit inserts its FP into the target cell membrane to change its conformation. Its HR1 helix then forms a homotrimer with an exposed surface that has three highly conserved hydrophobic grooves, and binds with HR2 to form a six-helix bundle (6-HB) core structure, which facilitates fusion by bringing the viral and cell membranes into close proximity.<sup><xref ref-type="bibr" rid="CR69">69</xref></sup> The genetic material of MERS-CoV then enters the host cell via the fusion pore.<sup><xref ref-type="bibr" rid="CR69">69</xref></sup></p><p id="Par23">SARS-CoV-2, which causes COVID-19, is a spherical betacoronavirus with a diameter of 60&#x02013;140&#x02009;nm and unique spikes ranging from 9 to 12&#x02009;nm.<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> Its RNA has the typical betacoronavirus organization, containing a 5&#x02032; UTR, a gene encoding the replicase complex (ORF1a/b), the S gene, E gene, M gene, and N gene, a 3&#x02032; UTR, and several unidentified nonstructural ORFs.<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR75">75</xref></sup> The length of the sequences is 265&#x02009;nt for the 5&#x02032; terminal region, 229&#x02009;nt for the 3&#x02032; terminal region, 3822&#x02009;nt for the S gene, 228&#x02009;nt for the E gene, 669&#x02009;nt for the M gene, and 1260&#x02009;nt for the N gene.<sup><xref ref-type="bibr" rid="CR75">75</xref></sup> The 21,291-nt-long ORF1a/b gene contains 16 predicted NSPs.<sup><xref ref-type="bibr" rid="CR75">75</xref></sup> Similar to SARS-CoV, there is a predicted ORF8 gene that is 366&#x02009;nt in length and located between the M and N ORF genes.<sup><xref ref-type="bibr" rid="CR75">75</xref></sup> Nucleotides 1, 1029, and 1652 may be the recombination breakpoints because based on the fragments from nt 1 to nt 1029 and nt 1652 to the end, SARS-CoV-2 seems to be related to bat-SL-CoVZC45 and bat-SL-CoVZXC21; however, when considering the region from nt 1030 to nt 1651, SARS-CoV-2 is mostly likely to be grouped with SARS-CoV and bat SARS-like CoVs. More research is required to analyze the recombination of the genome as a whole.<sup><xref ref-type="bibr" rid="CR75">75</xref></sup> With over 10% of its conserved replicase complex being different from those of other betacoronaviruses, SARS-CoV-2 solely occupies a newly created subclade within the <italic>Sarbecovirus</italic> subgenus.<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR75">75</xref></sup> Bats may be its natural host, but owing to several arguments including the complicated environment in the wet markets in Wuhan, this remains unclear, and further research is needed.<sup><xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR75">75</xref>&#x02013;<xref ref-type="bibr" rid="CR77">77</xref></sup> The free energy of the spike protein of SARS-CoV-2 is much lower than that of SARS-CoV, indicating that SARS-CoV-2 is more stable than SARS-CoV.<sup><xref ref-type="bibr" rid="CR78">78</xref></sup> The high similarity of the RBD sequences and of the spike protein structures between SARS-CoV-2 and SARS-CoV,<sup><xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR75">75</xref>,<xref ref-type="bibr" rid="CR79">79</xref></sup> also the simulation of the spike protein of SARS-CoV-2 binding to ACE2,<sup><xref ref-type="bibr" rid="CR80">80</xref></sup> the receptor of SARS-CoV, and results shown that ACE2 plays a vital role in SARS-CoV-2 entry into HeLa cells,<sup><xref ref-type="bibr" rid="CR76">76</xref></sup> indicating that SARS-CoV-2 also uses ACE2 for cell entry. Structural modeling of the ACE2-B0AT1 complex (B0AT1 is used to obtain stable ACE2) suggests that the complex can bind two S proteins simultaneously, providing important clues to the molecular basis of coronavirus recognition and infection.<sup><xref ref-type="bibr" rid="CR81">81</xref></sup> The RBD-ACE2 binding free energy for SARS-CoV-2 is significantly lower than that for SARS-CoV, in accordance with the fact that SARS-CoV-2 is more infectious than SARS-CoV.<sup><xref ref-type="bibr" rid="CR78">78</xref></sup> A recent study found that CD147, a kind of TM glycoprotein, facilitates cell entry of SARS-CoV-2 functionally, and its affinity constant with the S protein is 1.85&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;7</sup>&#x02009;M.<sup><xref ref-type="bibr" rid="CR82">82</xref></sup> Table <xref rid="Tab1" ref-type="table">1</xref> shows a comparison of the structures of SARS-CoV, MERS-CoV, and SARS-CoV-2. The specific function of the SARS-CoV-2 proteins, including S, E, M, and N proteins, need further study.<table-wrap id="Tab1"><label>Table 1</label><caption><p>The comparison of the structural proteins of SARS-CoV, MERS-CoV, and SARS-CoV-2</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Virus</th><th colspan="8">Structural proteins</th><th>References</th></tr></thead><tbody><tr><td rowspan="8">SARS-CoV</td><td rowspan="5">S protein</td><td rowspan="2">S1 subunit</td><td>The RBD (residues 318&#x02013;510)</td><td rowspan="2">Cell receptor (ACE2) binding</td><td rowspan="5">ACE2</td><td rowspan="5" colspan="3">Comprises 805 amino acids and contains a single catalytic domain</td><td rowspan="5"><sup><xref ref-type="bibr" rid="CR58">58</xref></sup></td></tr><tr><td>The RBM (residues 424&#x02013;494)</td></tr><tr><td rowspan="3">S2 subunit</td><td>FP</td><td rowspan="3">The fusion of virus and target cell membrane</td></tr><tr><td>HR1 (residues 892&#x02013;1013)</td></tr><tr><td>HR2 (residues 1145&#x02013;1195)</td></tr><tr><td/><td rowspan="1" colspan="2">N protein</td><td colspan="5">Combines with viral RNA to form a nucleocapsid</td><td rowspan="3"><sup><xref ref-type="bibr" rid="CR56">56</xref></sup></td></tr><tr><td/><td rowspan="1" colspan="2">M protein</td><td rowspan="2" colspan="2">Play important roles in viral assembly</td><td rowspan="2" colspan="2"/><td rowspan="2"/></tr><tr><td/><td rowspan="1" colspan="2">E protein</td></tr><tr><td rowspan="10">MERS-CoV</td><td rowspan="7">S protein</td><td rowspan="2">S1 subunit</td><td>The RBD (residues 367&#x02013;588)</td><td rowspan="2">Cell receptor (DPP4) binding</td><td rowspan="2">DPP4</td><td rowspan="2" colspan="3">N-terminal hydrolase</td><td rowspan="10"><sup><xref ref-type="bibr" rid="CR68">68</xref>,<xref ref-type="bibr" rid="CR69">69</xref>,<xref ref-type="bibr" rid="CR70">70</xref>,<xref ref-type="bibr" rid="CR71">71</xref></sup></td></tr><tr><td>The RBM (residues 484&#x02013;567)</td></tr><tr><td rowspan="5">S2 subunit</td><td>FP (residues 943&#x02013;982)</td><td rowspan="2">The fusion of virus and target cell membrane</td><td rowspan="2"/><td rowspan="2" colspan="3"/></tr><tr><td>HR1 (residues 984&#x02013;1104)</td></tr><tr><td>HR2 (residues 1246&#x02013;1295)</td><td rowspan="3"/><td rowspan="3"/><td rowspan="3" colspan="3">C-terminal &#x003b2;-propeller domain</td></tr><tr><td>Transmembrane domain (residues 1296&#x02013;1317)</td></tr><tr><td>Intracellular domain (residues 1318&#x02013;1353)</td></tr><tr><td/><td rowspan="1" colspan="2">N protein</td><td colspan="5">Binds to the RNA genome to form a nucleocapsid</td></tr><tr><td/><td rowspan="1" colspan="2">M protein</td><td colspan="5">Is important in viral assembly, the formation of the viral envelope, and the formation of the viral core</td></tr><tr><td/><td rowspan="1" colspan="2">E protein</td><td colspan="5">Plays an important role in intracellular trafficking, host recognition, viral assembly, and virus budding</td></tr><tr><td rowspan="10">SARS-CoV-2</td><td rowspan="7">S protein</td><td rowspan="2">S1 subunit</td><td>The RBD</td><td rowspan="2">Cell receptor (ACE2) binding</td><td rowspan="7">ACE2</td><td rowspan="7" colspan="3">comprises 805 amino acids and contains a single catalytic domain</td><td rowspan="7"><sup><xref ref-type="bibr" rid="CR78">78</xref>&#x02013;<xref ref-type="bibr" rid="CR80">80</xref></sup></td></tr><tr><td>The RBM</td></tr><tr><td rowspan="5">S2 subunit</td><td>FP</td><td rowspan="5">The fusion of virus and target cell membrane</td></tr><tr><td>HR1</td></tr><tr><td>HR2</td></tr><tr><td>Transmembrane domain</td></tr><tr><td>Connector domain</td></tr><tr><td/><td rowspan="1" colspan="2">N protein</td><td colspan="5">Combines with viral RNA to form a nucleocapsid</td><td rowspan="3"><sup><xref ref-type="bibr" rid="CR75">75</xref></sup></td></tr><tr><td/><td rowspan="1" colspan="2">M protein</td><td rowspan="2" colspan="5">Play important roles in viral assembly</td></tr><tr><td/><td rowspan="1" colspan="2">E protein</td></tr></tbody></table></table-wrap></p><p id="Par24">In conclusion, SARS-CoV, MERS-CoV, and SARS-CoV-2 are similar in structure. Their major proteins are structural proteins, including the S, E, M, and N proteins, accessory protein, and NSPs (NSP1&#x02013;16). All these viruses rely on the S protein to identify cell targets and fuse with membranes. Their S proteins are composed of S1 and S2 subunits. The S1 subunit contains an NTD and a C-domain, in which there is an RBD. The accessory subdomain of the C-domain is a hypervariable region for receptor recognition and is called the RBM. The difference is that SARS-CoV recognizes ACE2, SARS-CoV-2 recognizes ACE2 and CD147, but MERS recognizes DPP4, which results from the difference between the accessory subdomains of SARS-CoV, SARS-CoV-2, and MERS-CoV. The function of the accessory and nonstructural proteins of these three viruses is related to viral replication and assembly, hence linked to virulence.</p></sec><sec id="Sec7"><title>Pathogenesis of SARS-CoV, MERS-CoV, and SARS-CoV-2</title><p id="Par25">SARS-CoV and SARS-CoV-2 are nearly identical in terms of invasion and self-replication, whereas MERS-CoV has different targets. The cellular receptor of SARS-CoV and SARS-CoV-2 is ACE2, plus CD147 for SARS-CoV-2, while that of MERS-CoV is DPP4. The human ACE2 protein is a typical zinc metallopeptidase that comprises 805 amino acids and contains a single catalytic domain. It is a type I integral membrane glycoprotein that is oriented with an extracellular N terminus and a catalytic site that functions in metabolizing circulating peptides.<sup><xref ref-type="bibr" rid="CR83">83</xref></sup> It is believed that there is a virus-binding hot spot on ACE2 that is not pre-existent or preorganized but is induced to form upon virus binding.<sup><xref ref-type="bibr" rid="CR84">84</xref></sup> The hot spot consists of a salt bridge surrounded by hydrophobic tunnel walls. The general structural features of the hot spot favor virus binding: it is located in a region on ACE2 that is furthest from the membrane, relatively flat, and free of glycosylation and is thereby easily accessible to viruses. The hot spot is mainly an intrinsic property of ACE2, but it is also a dynamic structure and receives structural contributions from both ACE2 and the viruses, with the contributions of ACE2 being more pronounced. DPP4 is a type II transmembrane glycoprotein that consists of approximately 766 amino acids. DPP4 contains an N-terminal hydrolase and a C-terminal &#x003b2;-propeller domain composed of eight lancets.<sup><xref ref-type="bibr" rid="CR74">74</xref></sup> The S protein RBD binds to the side surface of the DPP4 propeller and the amino acid residues in lancets 4 and 5, including K267, Q286, T288, R317, R336, Q344, A291, L294, and I295.<sup><xref ref-type="bibr" rid="CR74">74</xref></sup></p><p id="Par26">The pathogenic mechanism of SARS-CoV is believed to include two parts: the virus injures target cells directly, and subsequent immune system dysfunction leads to indirect injury.<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> SARS-CoV spreads via droplet and contact transmission and via the fecal&#x02013;oral route. Through droplet inhalation, the virus enters the respiratory tract and invades epithelial cells. Infection and replication of the virus and local inflammatory changes contribute to lung tissue damage. Subsequently, SARS-CoV infects circulating and resident immune cells. The key cells in this step consist mainly of T cells and macrophages. The viruses are then carried to other organs, including secondary lymphoid organs, by these circulating immune cells.<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> SARS-CoV resembles HIV because both viruses attack immune cells and cause immunodeficiency.<sup><xref ref-type="bibr" rid="CR42">42</xref></sup></p><p id="Par27">SARS-CoV causes lung injury mainly by inhibiting the function of ACE2. The virus binds to ACE2 via the spike protein, downregulating its function and contributing to lung injury. ACE2 is an important component of the renin&#x02013;angiotensin system (RAS). In this system, angiotensinogen is first converted to angiotensinI (AngI) by renin, and then AngIis converted to Ang II under the influence of ACE2. ACE2 downregulates the levels of AngI and Ang II, which can bind to the Ang II type I (AT1) receptor and cause certain types of lung injury, mainly pulmonary hypertension, pulmonary fibrosis, and acute lung injury.<sup><xref ref-type="bibr" rid="CR85">85</xref></sup> Ang II can directly induce pulmonary artery smooth muscle cells to grow or proliferate rapidly through AT1, thus causing pulmonary hypertension.<sup><xref ref-type="bibr" rid="CR86">86</xref></sup> Ang II contributes to pulmonary fibrosis by promoting the expression of the profibrotic cytokine transforming growth factor-b1, causing fibroblasts to convert to myofibroblasts and accumulate collagen.<sup><xref ref-type="bibr" rid="CR70">70</xref></sup> Several strategies can be used by the virus to escape the innate immune response. Normally, viral pathogen-associated molecular patterns (PAMPs) are detected by host pattern recognition receptors (PRRs). PAMPs include viral dsRNA and mRNA, and PRRs include retinoic acid-inducible gene I protein (RIG-I) and melanoma differentiation-associated protein 5 (MDA5). Production of type I IFN is induced via the nuclear factor-&#x003ba;B (NF-&#x003ba;B) pathway. When IFN binds to the IFN&#x003b1;/&#x003b2; receptor, signal transducer and activator of transcription (STAT) proteins are activated, which increases the production of other antiviral proteins and thus blocks SARS-CoV replication for further infection.<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> Additionally, SARS-CoV could encode several proteins that hinder the signaling cascades downstream of PRRs.</p><p id="Par28">The cell receptor of MERS-CoV is DPP4, which is widely expressed on epithelial cells in the prostate, alveoli, kidneys, liver, and small intestine and on activated leukocytes; thus, the range of MERS-CoV tissue tropism is broader than that of any other similar coronavirus. MERS-CoV infection of dendritic cells and macrophages can lead to the continuous production of proinflammatory cytokines and chemokines (such as TNF-&#x003b1;, IL-6, CXCL-10, CCL-2, CCL-3, CCL-5, and IL-8).<sup><xref ref-type="bibr" rid="CR87">87</xref></sup> Compared to SARS-CoV infection, MERS-CoV infection can cause higher expression levels of IL-12, IFN-&#x003b3;, IP-10/CXCL-10, MCP-1/CCL-2, MIP-1&#x003b1;/CCL-3, RANTES/CCL-5, and IL-8.<sup><xref ref-type="bibr" rid="CR87">87</xref></sup> Induction of immune cell-recruiting cytokines/chemokines might lead to the infiltration of a large number of immune cells into the lower respiratory tract, causing severe inflammation and tissue damage.<sup><xref ref-type="bibr" rid="CR87">87</xref></sup> MERS-CoV can also infect T cells and lead to apoptosis, avoiding the host immune response and facilitating faster spread.<sup><xref ref-type="bibr" rid="CR88">88</xref></sup></p><p id="Par29">MERS-CoV has also evolved a mechanism to escape the host cell immune system. When host sensors initiate signaling pathways, transcription of type I IFN genes begins, and the type I IFN response, which is an essential component of antiviral innate immunity, is initiated.<sup><xref ref-type="bibr" rid="CR89">89</xref>&#x02013;<xref ref-type="bibr" rid="CR91">91</xref></sup> IFN activates the transcription of numerous IFN-stimulated genes (ISGs) and synthesizes 2&#x02032;,5&#x02032;-oligoadenylate (2-5A), which causes RNase L activation.<sup><xref ref-type="bibr" rid="CR91">91</xref>&#x02013;<xref ref-type="bibr" rid="CR93">93</xref></sup> Activated RNase L can cleave both viral and host ssRNA, leading to translation stagnation and apoptosis and limiting virus replication and transmission in vitro and in vivo.<sup><xref ref-type="bibr" rid="CR92">92</xref>,<xref ref-type="bibr" rid="CR94">94</xref></sup> However, the MERS-CoV protein NS4b has phosphodiesterase activity and antagonizes RNase L via enzymatic degradation, leading to inference with IFN signaling. Although NS4b is mainly expressed in the nucleus, the expression level of the NS4b protein in the cytoplasm is sufficient to prevent activation of RNase L.<sup><xref ref-type="bibr" rid="CR88">88</xref></sup> In addition, the MERS-CoV M, ORF4a, ORF4b, and ORF5 proteins are reported to be strong IFN antagonists, among which the ORF4a, ORF4b, and ORF5 proteins inhibit both type I IFN induction<sup><xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR95">95</xref>,<xref ref-type="bibr" rid="CR96">96</xref></sup> and NF-&#x003ba;B signaling pathways, which are similar to the type I IFN signaling pathway,<sup><xref ref-type="bibr" rid="CR96">96</xref></sup> providing a possible mechanism for MERS-CoV evasion of innate immunity.<sup><xref ref-type="bibr" rid="CR88">88</xref>,<xref ref-type="bibr" rid="CR96">96</xref></sup></p><p id="Par30">For SARS-CoV-2, the first cluster of patients was believed to be associated with a seafood market.<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> However, due to the identification of patients without direct exposure to the market, transmission between humans was proven.<sup><xref ref-type="bibr" rid="CR97">97</xref></sup> Hospital-related transmission has also been detected via infected medical workers and hospitalized patients. Main routes of transmission include respiratory droplets, close contact, and extended exposure to aerosol environments loaded with high concentrations of virions. In addition to transmission through the respiratory tract, exposure of unprotected eyes to SARS-CoV-2 might cause acute respiratory infection.<sup><xref ref-type="bibr" rid="CR98">98</xref></sup> Notably, the virus can be transmitted during the incubation period.<sup><xref ref-type="bibr" rid="CR99">99</xref></sup></p><p id="Par31">The TM protease serine type 2 (TMPRSS2) primes the S protein of SARS-CoV-2 for cell entry.<sup><xref ref-type="bibr" rid="CR100">100</xref></sup> Based on analysis of the ACE2 RNA expression profile in normal human lungs, SARS-CoV-2 mainly infects type II alveolar (AT2) cells (only 0.64% of human lung cells can express ACE2, 83% of which are AT2 cells), and they express many other genes that facilitate SARS-CoV-2 infection;<sup><xref ref-type="bibr" rid="CR101">101</xref></sup> moreover, CD147 was also reported that it probably functionally facilitates cell entry of SARS-CoV-2.<sup><xref ref-type="bibr" rid="CR82">82</xref></sup></p><p id="Par32">High expression of ACE2 has also been detected in cells of the digestive system, such as upper esophageal cells; accordingly, this system is a potential route of infection.<sup><xref ref-type="bibr" rid="CR102">102</xref></sup> In addition to the lungs and intestines, other organs, such as the heart, esophagus, kidney, bladder, testis, ileum, and adipose tissue, also express ACE2, and the expression level is higher than that in the lungs.<sup><xref ref-type="bibr" rid="CR103">103</xref>,<xref ref-type="bibr" rid="CR104">104</xref></sup> Certain tumor tissues have higher expression of ACE2, making cancer patients more vulnerable than other people.<sup><xref ref-type="bibr" rid="CR104">104</xref></sup></p><p id="Par33">In conclusion, SARS-CoV and SARS-CoV-2 bind cells expressing ACE2. They affect the RAS system due to the affinity for ACE2 (much stronger with SARS-CoV-2 than with SARS-CoV), leading to the onset of symptoms. MERS-CoV causes symptoms by producing inflammatory cytokines and invading T cells. The specific pathogenic mechanisms of these three viruses are illustrated in Fig. <xref rid="Fig4" ref-type="fig">4</xref>.<fig id="Fig4"><label>Fig. 4</label><caption><p>Pathogenesis of SARS-CoV, MERS-CoV, and SARS-CoV-2. SARS-CoV and SARS-CoV-2 play a pathogenic role by inhibiting ACE2. Under the influence of renin and ACE, angiotensinogen is converted into Ang II. Through the AT1 receptor, Ang II acts as a lung injury-promoting factor, and in some cases, may cause vascular constriction, an inflammatory response, cell proliferation, fibrosis, and apoptosis of alveolar epithelial cells, resulting in diseases such as pulmonary hypertension, pulmonary fibrosis, and acute lung injury. ACE2 converts Ang II into Ang (1&#x02013;7), and through the MAS receptor, Ang (1&#x02013;7) play roles in vasodilation, antiproliferative activity, and antioxidant activity. SARS-CoV downregulates the activity of ACE2 and causes an increase in the amount of Ang II and lung injury. MERS-CoV infection of dendritic cells and macrophages can lead to the continuous production of pro-inflammatory cytokines and chemokines, leading to a large number of immune cells infiltrating a patient&#x02019;s lower respiratory tract, causing severe inflammation and tissue damage. MERS-CoV can infect T-cells from human lymphoid organs and causes the peripheral blood inducing apoptosis by intrinsic and extrinsic pathways, thus avoiding host immune response</p></caption><graphic xlink:href="41392_2020_190_Fig4_HTML" id="d30e1553"/></fig></p></sec></sec><sec id="Sec8"><title>Diagnosis and therapy</title><sec id="Sec9"><title>Diagnostic methods</title><p id="Par34">In addition to clinical manifestations, definitive diagnosis and confirmation of a coronavirus infection requires specific testing. The criteria for the diagnosis of SARS from the WHO include (1) fever higher than 38&#x02009;&#x000b0;C or history of such in the past 2 days, (2) radiological evidence of new infiltrates consistent with pneumonia, (3) chills, cough, malaise, myalgia, or known history of exposure, and (4) positive tests for by at least one assay. As for MERS, the criteria for the diagnosis according to the WHO include (1) fever, cough, and hospitalization with suspicion of lower respiratory tract lesion, (2) history of contact with probable or confirmed cases, (3) history of travel or residence within the Arabian Peninsula, and (4) positive tests by a PCR-based detection method using respiratory samples, such as nasopharyngeal swabs, nasopharyngeal or tracheal aspirates, bronchoalveolar lavage (BAL) and induced sputum, or by serological tests such as the rapid immunochromatographic assay using highly selective monoclonal antibodies at room temperature. The initial criteria for the diagnosis of SARS included (1) a history of travel or residence in Wuhan within 2 weeks before the onset of illness, (2) exposure to patients from Wuhan with fever and respiratory symptoms within 2 weeks before the onset of illness or the existence of clusters of diseases, (3) fever accompanied by radiographic features of pneumonia, a normal or decreased total number of white blood cells, or a decreased lymphocyte count, and (4) fluorescence PCR testing positive for nucleic acids of SARS-CoV-2.<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR105">105</xref>&#x02013;<xref ref-type="bibr" rid="CR107">107</xref></sup></p><p id="Par35">Early diagnosis of MERS is difficult, but several highly specific and sensitive molecular and serologic assays exist for diagnosis in both animals and humans.<sup><xref ref-type="bibr" rid="CR108">108</xref></sup> Among them, a rapid immunochromatographic assay can detect MERS-CoV antigens based on the detection of the MERS-CoV nucleocapsid protein in a short time frame; the relative sensitivity and specificity of this test are 93.9 and 100%, respectively.<sup><xref ref-type="bibr" rid="CR105">105</xref></sup></p><p id="Par36">Nucleic acid tests, such as real-time PCR tests, were mostly used to detect virus in the early stage of the outbreak of SARS-CoV-2, although this approach requires a relatively long time and is not conducive to accelerating diagnosis or large-scale application. Therefore, alternative, rapid diagnostic kits for SARS-CoV-2 may be used. For example, the Colloidal Gold Detection Kit uses serum, plasma, or whole blood samples to detect IgM/IgG antibodies for diagnosis on the 7th day of infection or the 3rd day after onset and requires only 15&#x02009;min. The nucleic acid detection kit for six respiratory viruses, including SARS-CoV-2 and influenza A virus, uses thermostatic amplifier chips for diagnosis. By detecting different infections, it may help distinguish people with influenza from those with other viral infections. A newly developed detection method, Nanopore Targeted Sequencing, also has the potential for efficiently detecting viruses in a reasonable time. Moreover, it could identify 40 other respiratory viruses and monitor changes in virulence and transmissibility caused by viral mutations.<sup><xref ref-type="bibr" rid="CR109">109</xref></sup></p></sec><sec id="Sec10"><title>Therapeutic agents</title><p id="Par37">All patients should be treated in isolation.<sup><xref ref-type="bibr" rid="CR53">53</xref></sup> Based on previous studies, drugs may be developed to inhibit cell entry. Several strategies have been investigated to identify specific antivirals targeting the S protein, including MERS-RBD-targeted nAbs that block viral attachment, peptide inhibitors targeting S2 to prevent the formation of the fusion core, and small molecules without defined mechanisms.<sup><xref ref-type="bibr" rid="CR110">110</xref></sup> sDPP4 has been found to bind MERS-CoV RBD with high affinity, suggesting that sDPP4 could serve as a blocker for MERS-CoV attachment to and entry into cells.<sup><xref ref-type="bibr" rid="CR111">111</xref>,<xref ref-type="bibr" rid="CR112">112</xref></sup> One study reported a monoclonal antibody, 7D10, that binds to the NTD to inhibit cellular entry of MERS-CoV.<sup><xref ref-type="bibr" rid="CR113">113</xref></sup> Experiments have shown that 7D10 not only inhibits the binding of MERS-CoV to cells but also has effects after viral-cell attachment. 7D10 inhibits virus invasion by blocking the binding of the S1 subunit to the receptor and interfering with the conformational transformation of the S2 subunit when the virus fuses with the cell membrane.<sup><xref ref-type="bibr" rid="CR113">113</xref></sup> A peptide fragment spanning residues 736&#x02013;761 of the S protein exerts neutralization activity by inhibiting membrane fusion and the entry of MERS-CoV, suggesting that it is possible to develop vaccines targeting this neutralizing epitope.<sup><xref ref-type="bibr" rid="CR114">114</xref></sup> Griffithsin, a lectin derived from red algae, binds to oligosaccharides on the surface of SARS-CoV S protein and may also prove effective against SARS-CoV-2.<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR115">115</xref></sup> Researchers found that antibodies raised against SARS-CoV, such as CSS-2, -3, -4, and -5, could cross-neutralize SARS-CoV-2 by reducing S-driven cell entry, although the efficiency was lower than that observed for SARS-CoV.<sup><xref ref-type="bibr" rid="CR100">100</xref></sup> Meplazumab, an anti-CD147 humanized antibody, binds with the CD147 in competition with the S protein,<sup><xref ref-type="bibr" rid="CR116">116</xref></sup> thus significantly inhibiting virus from invading cells and reducing the time of negative conversion.<sup><xref ref-type="bibr" rid="CR82">82</xref>,<xref ref-type="bibr" rid="CR106">106</xref></sup> Chloroquine could effectively inhibit SARS-CoV-2 in vitro, and hydroxychloroquine was even more potent than chloroquine.<sup><xref ref-type="bibr" rid="CR117">117</xref>,<xref ref-type="bibr" rid="CR118">118</xref></sup> Hydroxychloroquine could significantly help reduce the virus load, and azithromycin could reinforce its effect.<sup><xref ref-type="bibr" rid="CR119">119</xref></sup> Arbidol could also contribute to condition improvement.<sup><xref ref-type="bibr" rid="CR120">120</xref></sup> Note that these studies were generally limited and further trials and development are necessary.</p><p id="Par38">Protease inhibitors also have the potential for coronavirus therapeutics. Protease inhibitors, including disulfiram, lopinavir, and ritonavir, have been reported to be effective against SARS and MERS, and disulfiram, a drug for alcohol dependence, was reported to inhibit the papain-like protease (PLpro) of MERS-CoV and SARS-CoV in cell cultures.<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR108">108</xref></sup> In vitro, SARS-CoV can be inhibited by both 6-mercaptopurine and 6-thioguanine targeting PLpro.<sup><xref ref-type="bibr" rid="CR121">121</xref></sup> When used together with ribavirin, the protease inhibitors lopinavir and ritonavir have improved the outcomes of patients with SARS compared with those achieved with the use of ribavirin alone.<sup><xref ref-type="bibr" rid="CR122">122</xref></sup> Such inhibitors are also being tested in patients infected with SARS-CoV-2, but whether these inhibitors effectively suppress 3CLpro and PLpro of SARS-CoV-2 remains controversial.<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> Drugs such as colistin, valrubicin, icatibant, bepotastine, epirubicin, epoprostenol, vapreotide, aprepitant, caspofungin, perphenazine, prulifloxacin, bictegravir, nelfinavir, and tegobuvir bind to the main protease of SARS-CoV-2, and thus, are potential candidates.<sup><xref ref-type="bibr" rid="CR123">123</xref></sup> Lianhua-Qingwen formula, a kind of traditional Chinese medicine, has been also recently described theoretically as a potential treatment candidate against the main virus protease.<sup><xref ref-type="bibr" rid="CR124">124</xref></sup> The serine protease inhibitor camostat mesylate could partly block SARS-CoV-2 infection of lung cells by inhibiting TMPRSS2.<sup><xref ref-type="bibr" rid="CR100">100</xref></sup></p><p id="Par39">Viral RNA synthesis blockers also have potential. Remdesivir has broad-spectrum activity against MERS-CoV and SARS-CoV in cell cultures and animal models and is currently in clinical development for the treatment of Ebola virus disease.<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR125">125</xref></sup> It was also reported positively based on a patient with SARS-CoV-2 infection in the US,<sup><xref ref-type="bibr" rid="CR126">126</xref></sup> and another study showed that it was able to inhibit the virus.<sup><xref ref-type="bibr" rid="CR117">117</xref></sup> Ribavirin is often used to treat SARS and MERS, but it is uncertain whether it is potent enough against COVID-19.<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR108">108</xref></sup> Regardless, when used alone, ribavirin has minimal activity against SARS-CoV and may cause strong side effects. It is often used together with corticosteroids.<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR127">127</xref></sup> A preclinical study of galidesivir (BCX4430), an adenosine analog, revealed antiviral activity against SARS-CoV and MERS-CoVCoV.<sup><xref ref-type="bibr" rid="CR115">115</xref></sup> A study of favipiravir (T-705), a guanine analog, proved its activity against SARS-CoV-2, and randomized trials of favipiravir plus interferon-&#x003b1; (ChiCTR2000029600), and favipiravir plus baloxavir marboxil (ChiCTR2000029544) are in progress.<sup><xref ref-type="bibr" rid="CR34">34</xref></sup></p><p id="Par40">Corticosteroids may be used to treat SARS patients to suppress lung inflammation; although this therapy is not associated with mortality in patients with MERS, it is associated with delayed clearance of MERS-CoV RNA.<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR128">128</xref></sup> Moreover, clinical evidence does not support the use of corticosteroids for COVID-19 treatment.<sup><xref ref-type="bibr" rid="CR129">129</xref></sup></p><p id="Par41">Regarding antibodies, plasma therapy using convalescent plasma from fully recovered patients is effective against these coronaviruses, including SARS-CoV-2.<sup><xref ref-type="bibr" rid="CR108">108</xref>,<xref ref-type="bibr" rid="CR130">130</xref></sup> Tocilizumab (anti-human IL-6 receptor) may curb immunopathology and trials are ongoing now.<sup><xref ref-type="bibr" rid="CR131">131</xref></sup> A study of novel monoclonal antibodies against the MERS-CoV spike protein suggests that mAbs can be utilized for the identification of specific mutations of MERS-CoV.<sup><xref ref-type="bibr" rid="CR132">132</xref></sup> Wang et al. provided an all-hydrocarbon-stapled peptide that likely mimics the native conformation of the C-terminal short &#x003b1;-helical region of the MERS-CoV S protein, which can block the formation of the hexameric coiled-coil fusion complex to inhibit viral-cell membrane fusion.<sup><xref ref-type="bibr" rid="CR133">133</xref>,<xref ref-type="bibr" rid="CR134">134</xref></sup></p><p id="Par42">Current treatments for SARS mainly include ribavirin, IFN &#x003b1;, plasma therapy, host-directed therapies, and systemic corticosteroids.<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR41">41</xref></sup> Due to the lack of clinical trial data, adequate supportive care supplemented with different combinations of drugs remains the main treatment for patients.<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR41">41</xref></sup></p><p id="Par43">For MERS, despite many studies in humans, there is no consensus on the best treatment; thus, randomized clinical trials are needed to assess potential treatment options.<sup><xref ref-type="bibr" rid="CR134">134</xref></sup> Several therapeutics are in development, including convalescent plasma, lopinavir/ritonavir, ribavirin, IFN and novel therapies, including polyclonal antibodies and broad-spectrum antivirals.<sup><xref ref-type="bibr" rid="CR108">108</xref></sup> Antimicrobial peptides (AMPs) may be used as alternative therapeutic agents,<sup><xref ref-type="bibr" rid="CR135">135</xref></sup> and many have been effective even against bacterial proteases agents.<sup><xref ref-type="bibr" rid="CR136">136</xref></sup> Antiviral drugs with effective activity in vitro include neutralizing monoclonal antibodies, antiviral peptides, mycophenolic acid, lopinavir, IFN, ribavirin, nitazoxamide, mycophenolate mofetil (MMF), alisporivir, silvestro, and corticosteroids.<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR59">59</xref></sup></p><p id="Par44">Although there is no agreement on the most ideal treatment option to cure COVID-19, much research activities and pursued routes are underway.</p></sec><sec id="Sec11"><title>Potential host-targeted agents</title><p id="Par45">The host-directed strategy is another approach for limiting viral replication. Host proteases such as cathepsin B and cathepsin L can cleave the spike protein of SARS-CoV. Drugs such as camostat inhibit host serine proteases and then interfere with the entry of SARS-CoV, but they may cause many significant side effects.<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR135">135</xref></sup> Pegylated IFN &#x003b1;-2a and -2b may be used to stimulate innate antiviral responses in patients, and chloroquine, an approved immune modulator, was reported to have inhibitory effects against SARS-CoV-2 under certain conditions.<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> Researchers have also proposed that some commercially available drugs with suitable safety profiles, such as metformin, glitazones, fibrates, sartans, and atorvastin, as well as nutrient supplements and biologics, might reduce immunopathology, boost immune responses, and prevent or curb ARDS. In addition, ongoing cellular therapies using mesenchymal stromal cells from allogeneic donors have been shown to reduce nonproductive inflammation and affect tissue regeneration and are being evaluated in phase 1/2 trials in patients with ARDS; these therapies may be assayed in SARS-CoV-2-infected patients.<sup><xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR137">137</xref>,<xref ref-type="bibr" rid="CR138">138</xref></sup> Expansion of antiviral T cells as cellular drugs could aid in preparing T cell products for adjunct treatment of patients with severe infection.<sup><xref ref-type="bibr" rid="CR40">40</xref></sup></p><p id="Par46">Overall, there are similarities and differences among the treatments for these three coronaviruses. Notably, we summarize the potential drugs and vaccines in Table <xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Potential drugs and vaccines against three coronaviruses</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2"/><th>SARS-CoV</th><th>MERS-CoV</th><th>SARS-CoV-2</th><th>References</th></tr></thead><tbody><tr><td>Potential virally targeted agents</td><td>Potential drugs inhibiting cell entry</td><td><p>CP-1</p><p>Griffithsin</p><p>CSS-2,3,4,5</p></td><td><p>HR2P</p><p>sDPP4</p><p>7D10</p></td><td><p>EK1</p><p>EK1C4</p><p>Griffithsin</p><p>CSS-2,3,4,5</p></td><td><sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR100">100</xref>,<xref ref-type="bibr" rid="CR111">111</xref>,<xref ref-type="bibr" rid="CR113">113</xref>,<xref ref-type="bibr" rid="CR115">115</xref>,<xref ref-type="bibr" rid="CR164">164</xref>,<xref ref-type="bibr" rid="CR165">165</xref></sup></td></tr><tr><td/><td>nAbs</td><td><p>CR3022</p><p>m396</p><p>80R</p><p>33G4</p></td><td><p>m336</p><p>MERS-4</p><p>MERS-27</p></td><td>CR3022</td><td><sup><xref ref-type="bibr" rid="CR160">160</xref>&#x02013;<xref ref-type="bibr" rid="CR163">163</xref></sup></td></tr><tr><td/><td>Protease inhibitors</td><td><p>Remdesivir</p><p>Ribavirin</p><p>Galidesivir</p><p>Lopinavir</p><p>Bananins</p><p>5-Hydroxychromone</p><p>derivatives</p><p>Disulfiram</p></td><td><p>Favipiravir</p><p>Ribavirin</p><p>Penciclovir</p><p>Remdesivir</p><p>Lopinavir</p><p>Ritonavir</p><p>Darunavir</p></td><td><p>Remdesivir</p><p>Ribavirin Galidesivir</p><p>Lopinavir Ritonavir</p><p>Camostat Mesylate</p></td><td><sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR111">111</xref>,<xref ref-type="bibr" rid="CR121">121</xref>,<xref ref-type="bibr" rid="CR122">122</xref></sup></td></tr><tr><td/><td>Viral RNA synthesis blockers</td><td/><td>Remdesivir</td><td/><td><sup><xref ref-type="bibr" rid="CR117">117</xref></sup></td></tr><tr><td/><td/><td colspan="2"><p>Ribavirin</p><p>Galidesivir (BCX4430)</p></td><td>Favipiravir (T-705)</td><td><sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR108">108</xref>,<xref ref-type="bibr" rid="CR115">115</xref>,<xref ref-type="bibr" rid="CR122">122</xref>,<xref ref-type="bibr" rid="CR126">126</xref></sup></td></tr><tr><td/><td>Other agents</td><td/><td>Convalescent plasma</td><td/><td><sup><xref ref-type="bibr" rid="CR108">108</xref></sup></td></tr><tr><td/><td/><td><p>Corticosteroids</p><p>6-mercaptopurine-6-thioguaninet</p><p>IFN&#x003b1;</p><p>Antiviral treatments</p></td><td><p>IFN&#x003b1;</p><p>Antimicrobial peptides (AMPs)</p><p>Mycophenolic acid</p><p>Nitazoxamide</p><p>Mycophenolate mofetil (MMF)</p></td><td/><td><sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR122">122</xref>,<xref ref-type="bibr" rid="CR133">133</xref>,<xref ref-type="bibr" rid="CR134">134</xref></sup></td></tr><tr><td colspan="2">Potential host-targeted agents</td><td colspan="3">Pegylated interferon alfa-2a; Pegylated interferon alfa-2b; Metformin; Glitazones; Fibrates; Sartans; Atorvastin; nutrient supplements; biologics; cellular therapies; IFN&#x003b1; together with immunoglobulins or thymosins;</td><td><sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR136">136</xref></sup></td></tr><tr><td colspan="2"/><td><p>Cathepsin B cathepsinL</p><p>Camostat</p></td><td/><td>Chloroquine</td><td><sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR100">100</xref>,<xref ref-type="bibr" rid="CR134">134</xref></sup></td></tr><tr><td>Spike-based vaccines</td><td/><td>A recombinant fusion protein (designated RBD-Fc) containing 193-amino acid RBD and a human IgG1 Fc fragment</td><td>Simian adenovirus vector vaccine (ChAdOx1);an Ad vector encoding MERS-CoV S1 extracellular domain (Ad5.MERS-S1);an RABV vector encoding S1 elicit antibody;RBD-based vaccines</td><td/><td><sup><xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR138">138</xref>,<xref ref-type="bibr" rid="CR139">139</xref>,<xref ref-type="bibr" rid="CR140">140</xref></sup></td></tr></tbody></table></table-wrap></p></sec><sec id="Sec12"><title>Vaccines</title><p id="Par47">Vaccination could be used to prevent infection or to reduce disease severity. Different kinds of vaccines, such as DNA vaccines, recombinant proteins, subunit vaccines, and inactivated viruses, were described.<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> However, the highly sophisticated immune evasion mechanisms of viral pathogens and their high mutation rates make human vaccine development a major challenge.<sup><xref ref-type="bibr" rid="CR136">136</xref></sup> The four NSPs (3CLpro, PLpro, helicase, and RdRp), which are key enzymes in the viral life cycle, and the S protein, which is responsible for receptor binding during cell entry, are attractive targets for developing vaccines against coronaviruses.<sup><xref ref-type="bibr" rid="CR115">115</xref></sup> Among them, the S protein is most commonly targeted.<sup><xref ref-type="bibr" rid="CR61">61</xref></sup></p><p id="Par48">Based on previous studies, it is believed that the S protein receptor-binding domain (S-RBD) located in the S1 subunit is an important target for the development of a SARS vaccine, especially the key neutralizing region, CND. Indeed, CND can induce a strong neutralizing antibody response and cross-protection against SARS-CoV mutants. One study showed that a recombinant fusion protein (designated RBD-Fc) containing the 193-amino acid RBD and a human IgG1 Fc fragment can induce highly potent antibody responses in immunized rabbits. The antibodies inhibited SARS-CoV infection (serum dilution of 1:10,240), and they are believed to be safer than other types of vaccines.<sup><xref ref-type="bibr" rid="CR139">139</xref></sup> Additionally, with chloroplast transgenic technology, it is possible to combine the fusion gene S-RBD and the carrier molecule cholera toxin B subunit into the tobacco chloroplast genome to obtain a chloroplast transgenic tobacco plant that stably expresses the oral SARS-CoV subunit vaccine.<sup><xref ref-type="bibr" rid="CR140">140</xref></sup> For MERS, vaccines based on the viral S protein include full-length S or S-trimer protein-based vaccines such as a full-length S-based simian adenovirus vector vaccine (ChAdOx1) and DNA vaccine (GLS-5300),<sup><xref ref-type="bibr" rid="CR61">61</xref></sup> S1-based vaccines such as an Ad vector encoding MERS-CoV S1 extracellular domain (Ad5.MERS-S1) and an RABV vector encoding an S1-elicited antibody,<sup><xref ref-type="bibr" rid="CR141">141</xref>,<xref ref-type="bibr" rid="CR142">142</xref></sup> RBD-based vaccines, and vaccines based on other regions. It has been confirmed that the S proteins of SARS-CoV and SARS-CoV-2 are quite similar, but researchers recently found that the three monoclonal antibodies developed to bind to the S protein of SARS-CoV, S230, m396, and 80R do not cross-react with the S protein RBD of SARS-CoV-2, suggesting that tailored vaccines and antibodies against SARS-CoV-2 must be designed.<sup><xref ref-type="bibr" rid="CR143">143</xref></sup></p><p id="Par49">DNA vaccines are also quite promising. Specific IgG antibodies against SARS-CoV can be promoted by the S gene DNA vaccine. As mentioned above, the S protein of SARS-CoV plays an important role during the pathogenic process, and synthetic peptides induced by DNA vaccine in <italic>Escherichia coli</italic> elicit specific antibodies against the SARS-CoV S protein which might provide another approach for further developing SARS-CoV vaccines.<sup><xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR144">144</xref></sup> To evaluate the safety and immunogenicity of a plasmid DNA vaccine (GLS-5300) that expresses the S protein of MERS-CoV, a phase I clinical trial on healthy volunteers was conducted in 2016, but the results were not reported. Another phase I trial utilizing the viral vector, Chimpanzee Adenovirus, Oxford University #1 (ChAdOx1), containing the MERS-CoV S protein expression gene was started by Oxford University in January 2018.<sup><xref ref-type="bibr" rid="CR145">145</xref></sup></p><p id="Par50">In addition, camel vaccines against MERS-CoV are a consideration. At present, at least two promising candidate camel vaccines are undergoing development, and field trial evaluation is in progress.<sup><xref ref-type="bibr" rid="CR108">108</xref>,<xref ref-type="bibr" rid="CR146">146</xref></sup> One study found that the RBD fragment covering spike residues 377&#x02013;588 is a key neutralizing receptor-binding fragment and an ideal candidate for MERS vaccines.<sup><xref ref-type="bibr" rid="CR147">147</xref></sup> Another potential neutralizing epitope is a peptide fragment covering 736&#x02013;761 residues of the S protein which blocks the membrane fusion and cellular entry of MERS-COV<sup><xref ref-type="bibr" rid="CR114">114</xref></sup> (Fig. <xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><p>The targets of the different drug candidates against the three coronaviruses. Common targets against the three coronaviruses are mainly the S protein and the S1/S2 subunits, PL protein, RdRp, 3CL protein, and Helicase. The figure shows drug candidates (in black) and vaccines (in red). Among them, Remdesivir has been trending in the news recently. It inhibits the RdRp, is in phase III for SARS-CoV-2, and may have an effect on the three viruses. Ribavirin in combination with a pegylated interferon may also have an effect against the three viruses. Ritonavir and Lopinavir, which inhibit the 3CLpro and are in phase III for SARS-CoV-2, have an effect on both SARS-CoV-2 and MERS-CoV. DNA vaccines and vaccines based on the S protein or subunits of the S protein are in development</p></caption><graphic xlink:href="41392_2020_190_Fig5_HTML" id="d30e2292"/></fig></p></sec><sec id="Sec13"><title>Other approaches</title><p id="Par51">Recombinant viruses may be employed to generate an immune response against the viruses. There are two kinds of recombinant viruses which are promising for designing a protective vaccine. The first is a defective or nonpathogenic vector capable of expressing viral proteins, and the second is a vector that can be assembled in a test tube to stimulate the assembly of virus-like particles.</p><p id="Par52">Adenosine deaminase (ADA), a kind of human enzyme, could interact with DPP4, therefore, ADA could compete with MERS-CoV as a natural antagonist when the virus attempts to bind to cells.<sup><xref ref-type="bibr" rid="CR148">148</xref></sup> In addition, anti-DPP4 can play a similar role,<sup><xref ref-type="bibr" rid="CR149">149</xref></sup> however, it is not practical to use this method in vivo because DPP4 has important functions in the regulation of several different signaling pathways.<sup><xref ref-type="bibr" rid="CR150">150</xref></sup></p></sec></sec><sec id="Sec14"><title>Perspectives and further directions</title><sec id="Sec15"><title>Questions concerning the coronavirus&#x02013;host interactions</title><p id="Par53">This topic has intrigued the community. Understanding certain mechanisms about virus interactions will support drug research activities. For instance, it was found that SARS-CoV-2 has a stronger, more rapid spreading ability than many known viruses. Is it possible that it invades host cells via additional novel routes, not limited to ACE2? For example, CD147 is probably involved in virus invasion.<sup><xref ref-type="bibr" rid="CR82">82</xref></sup> Is there an S-like protein involved in invasion? The affinity of the human ACE2 protein for the RBD of the new coronavirus is 10&#x02013;20 times higher than it is for that of the SARS virus, which likely explains why SARS-CoV-2 spreads more swiftly. There is a distinct insert present in the peptide fragment spanning of S1/S2 loop of the SARS-CoV-2 S protein, which is not shared the similarity with SARS-CoV or any SARS-related viruses. Does this peptide loop impact on the entry pathway type of SARS-CoV-2, compared to other known betacoronavirus lineage B? Furthermore, the S protein is likely cleaved during virus assembly and delivery to the cell surface by Golgi-resident proprotein convertases such as furin,<sup><xref ref-type="bibr" rid="CR151">151</xref></sup> which is different from the behavior of its close relatives. Furin is found in a variety of human tissues, including the lungs, liver, and small intestine. Therefore, which are exactly the cell types that SARS-CoV-2 may attack? Yet, in relation to the last two questions, it should be noted that studies are also necessary to investigate any possibility of receptor-independent virus entry.</p></sec><sec id="Sec16"><title>Potential targets and drugs against SARS-CoV-2</title><p id="Par54">The SARS-CoV-2 genome encodes nonstructural proteins, structural proteins, and accessory proteins. 3CLpro, PLpro, helicase, and RdRp, which belong to the first type, and the S protein, which belongs to the second, have been recognized as promising targets for developing antiviral agents against SARS-CoV and MERS-CoV, which therefore may be applied to SARS-CoV-2. Nonetheless, the rapid identification of effective interventions against SARS-CoV-2 is a major challenge. However, the subject of using currently known antiviral drugs has been frequently brought up by the community as a potential short-term strategy to combat SARS-CoV-2.</p><p id="Par55">Drugs affecting such targets and their status for SARS-CoV-2 are listed below. The main candidates as inhibitors of 3CLpro include lopinavir, ritonavir, darunavir, cobicistat, and ASC09F (phase III, in combination with oseltamivir, for SARS-CoV-2).<sup><xref ref-type="bibr" rid="CR152">152</xref></sup> Candidates as inhibitors of PLpro include thiopurine analogs, compound 6 (preclinical), and remdesivir (phase III for MARS-CoV).<sup><xref ref-type="bibr" rid="CR121">121</xref>,<xref ref-type="bibr" rid="CR153">153</xref></sup> Favipiravir, ribavirin (randomized trial for SARS-CoV-2), and remdesivir are among the candidate inhibitors of RdRp.<sup><xref ref-type="bibr" rid="CR118">118</xref></sup> Previously, compounds that may interfere with ATPase and helicase activities were reported (before COVID-19), such as bananins, 5-hydroxychromone derivatives, and triazole derivatives (preclinical).<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR78">78</xref></sup> Candidates that may suppress viral entry by targeting the S protein include peptide P9 and &#x003b1;-helical lipopeptides (preclinical),<sup><xref ref-type="bibr" rid="CR154">154</xref></sup> and those targeting the S2 subunit of the S protein mainly include HR1P, HR1M, HR1L, HR2L, HR2P, and HR2L (preclinical).<sup><xref ref-type="bibr" rid="CR155">155</xref></sup></p><p id="Par56">Due to the strong affinity between ACE2 receptor and the RBD of SARS-CoV-2, another opportunity might be through the development of antibodies to block ACE2. The second method is to use a large amount of soluble ACE2 to directly block the spike protein. The third method is to find a drug that directly inhibits the spike membrane fusion process, such as the AIDS drug enfuvirtide. The fourth approach is to identify an agent that inhibits the activity of disintegrin and metalloproteinase 17 (ADAM17), which may also prevent viral release and proliferation in cells and protect ACE2 and the lungs.<sup><xref ref-type="bibr" rid="CR87">87</xref></sup></p></sec><sec id="Sec17"><title>mRNA vaccine technology</title><p id="Par57">SARS-CoV-2 vaccines are already under development. The mRNA and DNA vaccines are promising approaches to prevent cellular invasion by similar coronaviruses in the future. In January 2020, the Coalition for Epidemic Preparedness Innovations (CEPI) announced three partnerships to develop a new coronavirus vaccine. Among them, Moderna and Inovio presented mRNA and DNA vaccine technologies, respectively. The goal of the three teams is to have at least one candidate vaccine capable of preventing coronavirus infection in 16 weeks, to be tested in a phase I clinical trial.</p><p id="Par58">Moderna&#x02019;s vaccine model is designed to use mRNAs to safely pre-expose the immune system to a small amount of encoded proteins usually generated by the pathogen, so that the immune system becomes prepared to fight future pathogens and prevent infection. The candidate genes developed by Moderna contain mRNAs, and combining multiple mRNAs into a single vaccine might be useful to rapidly induce responses, which is an approach that may be applied for future, emerging pandemic threats too. At the same time, because the mRNA in the cell will be degraded over time, the mRNA vaccine will not continue to produce antigen components for a long time, which can avoid the risk of continued stimulation of the immune system. Generally, mRNA vaccines are also described as simple to prepare and to yield remarkable results. Additional advantages, as well as disadvantages, of nucleic acid-based vaccines were described in detail. Furthermore, the basis of traditional vaccines, proteins or polysaccharides, cannot be straight forward applied at present against many pathogens. Therefore, mRNA vaccines would be suitable for achieving rapid, mass production of emergency vaccines in the event of a major epidemic. However, because RNA is easily degraded, inducing cells to absorb mRNA quickly is a challenge. In recent years, the method for delivery of mRNA into cells has been greatly improved, and Stemirna and Moderna have adopted nanolipid (LPP or LNP (lipid nanoparticle)) drug-loading technology. However, this is still to be developed for mRNAs. Furthermore, ensuring safety and effectiveness is another challenge for viral mRNA vaccines, and clinical validation will have to be carried out carefully.</p><p id="Par59">Moderna is a worldwide leader in mRNA therapy, with currently nine mRNA-type vaccine candidates (e.g., mRNA-1273 against SARS-CoV-2). The National Institutes of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) and the mRNA vaccine giant Moderna have teamed up to bring the new coronavirus vaccine possibly to phase II within a few months, and phase III late this year. Simultaneously, in January 2020, the Translational Medicine Platform of Dongfang Hospital affiliated with Tongji University cooperated with Stemirna (Shanghai) Biotechnology Co., Ltd. to rapidly promote the development of a new coronavirus mRNA vaccine. In February 2020, the Chinese scientific research team announced that animal testing of the newly developed coronavirus vaccine has begun. If animal testing goes well, this new vaccine will enter human clinical trials within a few months. Also in February 2020, Zhuhai Livanda Biotechnology Co., Ltd. announced that the first batch of new coronavirus mRNA vaccine standard samples completed during the Spring Festival had been delivered to relevant national authorities on for animal testing and efficacy verification. The researchers detected the production of target antibodies in mouse serum at day 12 following immunization. The company claimed that this was also the first time worldwide that new coronavirus vaccines developed based on mRNA technology have resulted in antibodies in animals. Livanda is currently pushing ahead with the project through extensive cooperation with the Academy of Military Medical Sciences, the Guangdong Provincial Institute of Supervision, and the Macau University of Science and Technology. The antigen used in its development is the same as that used by Moderna.</p></sec><sec id="Sec18"><title>DNA vaccine technology</title><p id="Par60">DNA vaccine technology may have many advantages (e.g., safe, fast, less technical barriers), along with potential limitations too.<sup><xref ref-type="bibr" rid="CR156">156</xref></sup> A phase I human clinical trial of the MERS-CoV vaccine has proven its safety and effectiveness.<sup><xref ref-type="bibr" rid="CR157">157</xref></sup> The DNA vaccine based on the SARS-CoV S protein developed by the team of Barney Graham and Gary Nabel of the US-NIH Vaccine Research Center (VRC) has achieved positive results in animal experiments and a clinical phase I trial.<sup><xref ref-type="bibr" rid="CR158">158</xref></sup><sup>,<xref ref-type="bibr" rid="CR159">159</xref></sup> Inovio Pharmaceuticals has accumulated extensive safety and immunogenicity data for MERS-CoV vaccine studies. Because of the high degree of similarity between MERS-CoV and SARS-CoV-2, lessons from such a vaccine development process may be beneficial for the development of a DNA vaccine against SARS-CoV-2. Since January 2020, Inovio has been collaborating with several experts and companies (some in China), and has currently already begun phase I clinical trials of the DNA vaccine INO-4800.</p></sec><sec id="Sec19"><title>Recombinant vaccines</title><p id="Par61">China&#x02019;s CanSino Biologics might be the leader as it was announced it has moved to phase II testing of a vaccine called Ad5-nCoV. The latter is currently often being reported as a DNA vaccine, but to be precise, it uses viral vectors (adenovirus) to deliver DNA related to SARS-CoV-2. Part of the project is carried out currently with the Chinese military medical research institute. The vaccine candidate is constructed using genetic engineering methods and defective human type 5 adenovirus as a vector that can express the SARS-CoV-2 S antigen, to stimulate the body to produce strong humoral or cellular immunity.</p></sec></sec><sec id="Sec20" sec-type="conclusion"><title>Conclusion</title><p id="Par62">SARS-CoV and MERS-CoV belong to subgroups 2b and 2c of the betacoronaviruses, respectively, and SARS-CoV-2 is a new member of betacoronaviruses, distinct from SARS-CoV and MERS-CoV. SARS-CoV and SARS-CoV-2 are similar in terms of invasion and self-replication, whereas MERS-CoV has different targets. The cellular receptor of SARS-CoV and SARS-CoV-2 is ACE2, plus CD147 for SARS-CoV-2, while that of MERS-CoV is DPP4 (CD26). All of them evolved a mechanism to escape the host cell immune system. SARS-CoV and SARS-CoV-2 affect the RAS system by suppressing ACE2, leading to the onset of symptoms. MERS-CoV causes symptoms by producing inflammatory cytokines and invading T cells. SARS-CoV, MERS-CoV, and SARS-CoV-2 infections have similar symptoms, including fever, cough, myalgia, and shortness of breath, among others. Current treatments for SARS mainly include IFN-&#x003b1;, antiviral treatments (e.g., ribavirin), plasma therapy, host-directed therapies, and systemic corticosteroids. For MERS, several therapeutics are in development, including convalescent plasma, lopinavir/ritonavir, ribavirin, IFN, and novel therapies, including polyclonal antibodies, broad-spectrum antivirals, and AMPs. For COVID-19, candidates mainly include drugs targeting the S protein, nonstructural proteins (3CLpro, PLpro, helicase, and RdRp), and viral RNA synthesis blockers such as Remdesivir and Ribavirin. Vaccines such as DNA vaccine, mRNA vaccine, and recombinant vaccines are being rapidly developed.</p><p id="Par63">So far this century, human beings have experienced several epidemic outbreaks, and each outbreak had a negative impact at different levels, including health, economy, and even psychology and human behavior. In the future, more precautious measures should be available to guide individuals and groups to take effective emergency measures and to support social stability, and physical and mental health. Furthermore, additional studies of coronaviruses and disease epidemics should continue, to support the preparation for future responses, medical therapies, vaccines, and methods of relieving personal anxiety. This review has highlighted several approaches, and the names and progress related to several compounds and biologics currently under research and development, as well as the companies and researchers involved in these efforts. For future directions, it has also described the differences and similarities, as well as the potential routes and possibilities for targeting each of the main three viruses investigated here.</p></sec></body><back><fn-group><fn><p>These authors contributed equally: Bin Chen, Er-Kang Tian, Bin He</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors gratefully acknowledge the financial support from the National Natural Science Foundation of China (Grant No. 31870836), and the 1.3.5 Project for Disciplines Excellence, West China Hospital, Sichuan University (ZYYC20005 to W.C.).</p></ack><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par64">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>S</given-names></name><etal/></person-group><article-title>Epidemiology, genetic recombination, and pathogenesis of coronaviruses</article-title><source>Trends Microbiol.</source><year>2016</year><volume>24</volume><fpage>490</fpage><lpage>502</lpage><?supplied-pmid 7125511?><pub-id pub-id-type="pmid">27012512</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>YI</given-names></name><etal/></person-group><article-title>Origins and evolution of the global RNA virome</article-title><source>mBio</source><year>2018</year><volume>9</volume><fpage>e02329-18</fpage><?supplied-pmid 30482837?><pub-id pub-id-type="pmid">30482837</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Classify viruses&#x02014;the gain is worth the pain</article-title><source>Nature</source><year>2019</year><volume>566</volume><fpage>318</fpage><lpage>320</lpage><?supplied-pmid 30787460?><pub-id pub-id-type="pmid">30787460</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erles</surname><given-names>K</given-names></name><name><surname>Toomey</surname><given-names>C</given-names></name><name><surname>Brooks</surname><given-names>HW</given-names></name><name><surname>Brownlie</surname><given-names>J</given-names></name></person-group><article-title>Detection of a group 2 coronavirus in dogs with canine infectious respiratory disease</article-title><source>Virology</source><year>2003</year><volume>310</volume><fpage>216</fpage><lpage>223</lpage><?supplied-pmid 12781709?><pub-id pub-id-type="pmid">12781709</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Hoek</surname><given-names>L</given-names></name></person-group><article-title>Human coronaviruses: what do they cause?</article-title><source>Antivir. Ther.</source><year>2007</year><volume>12</volume><fpage>651</fpage><lpage>658</lpage><?supplied-pmid 17944272?><pub-id pub-id-type="pmid">17944272</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>NS</given-names></name><etal/></person-group><article-title>Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People&#x02019;s Republic of China, in February, 2003</article-title><source>Lancet</source><year>2003</year><volume>362</volume><fpage>1353</fpage><lpage>1358</lpage><?supplied-pmid 14585636?><pub-id pub-id-type="pmid">14585636</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaki</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia</article-title><source>N. Engl. J. Med.</source><year>2012</year><volume>367</volume><fpage>1814</fpage><lpage>1820</lpage><?supplied-pmid 23075143?><pub-id pub-id-type="pmid">23075143</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drexler</surname><given-names>JF</given-names></name><name><surname>Corman</surname><given-names>VM</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name></person-group><article-title>Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS</article-title><source>Antivir. Res.</source><year>2014</year><volume>101</volume><fpage>45</fpage><lpage>56</lpage><?supplied-pmid 24184128?><pub-id pub-id-type="pmid">24184128</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P</given-names></name><etal/></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><year>2020</year><volume>579</volume><fpage>270</fpage><lpage>273</lpage><?supplied-pmid 7095418?><pub-id pub-id-type="pmid">32015507</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>X</given-names></name><etal/></person-group><article-title>Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>1620</fpage><?supplied-pmid 32221306?><pub-id pub-id-type="pmid">32221306</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>XL</given-names></name><etal/></person-group><article-title>On the origin and continuing evolution of SARS-CoV-2</article-title><source>Natl. Sci. Rev.</source><year>2020</year><pub-id pub-id-type="doi">10.1093/nsr/nwaa036</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China</article-title><source>Science</source><year>2003</year><volume>302</volume><fpage>276</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">12958366</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Wu, A. P. et al. Mutations, recombination and insertion in the evolution of 2019-nCoV. Preprint at 10.1101/2020.02.29.971101 (2020).</mixed-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wit</surname><given-names>E</given-names></name><name><surname>van Doremalen</surname><given-names>N</given-names></name><name><surname>Falzarano</surname><given-names>D</given-names></name><name><surname>Munster</surname><given-names>VJ</given-names></name></person-group><article-title>SARS and MERS: recent insights into emerging coronaviruses</article-title><source>Nat. Rev. Microbiol.</source><year>2016</year><volume>14</volume><fpage>523</fpage><lpage>534</lpage><?supplied-pmid 27344959?><pub-id pub-id-type="pmid">27344959</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>ACP</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Lau</surname><given-names>SKP</given-names></name><name><surname>Woo</surname><given-names>PCY</given-names></name></person-group><article-title>Global epidemiology of bat coronaviruses</article-title><source>Viruses</source><year>2019</year><volume>11</volume><fpage>174</fpage></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>ZQ</given-names></name><etal/></person-group><article-title>From SARS to MERS, thrusting coronaviruses into the spotlight</article-title><source>Viruses</source><year>2019</year><volume>11</volume><fpage>59</fpage></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LF</given-names></name><etal/></person-group><article-title>Review of bats and SARS</article-title><source>Emerg. Infect. Dis.</source><year>2006</year><volume>12</volume><fpage>1834</fpage><lpage>1840</lpage><?supplied-pmid 17326933?><pub-id pub-id-type="pmid">17326933</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Hazmi</surname><given-names>A</given-names></name></person-group><article-title>Challenges presented by MERS corona virus, and SARS corona virus to global health</article-title><source>Saudi J. Biol. Sci.</source><year>2016</year><volume>23</volume><fpage>507</fpage><lpage>511</lpage><?supplied-pmid 27298584?><pub-id pub-id-type="pmid">27298584</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease</article-title><source>Clin. Microbiol. Rev.</source><year>2015</year><volume>28</volume><fpage>465</fpage><lpage>522</lpage><?supplied-pmid 25810418?><pub-id pub-id-type="pmid">25810418</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baharoon</surname><given-names>S</given-names></name><name><surname>Memish</surname><given-names>ZA</given-names></name></person-group><article-title>MERS-CoV as an emerging respiratory illness: a review of prevention methods</article-title><source>Travel Med. Infect. Dis.</source><year>2019</year><volume>32</volume><fpage>101520</fpage></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azhar</surname><given-names>EI</given-names></name><etal/></person-group><article-title>The Middle East respiratory syndrome (MERS)</article-title><source>Infect. Dis. Clin. N. Am.</source><year>2019</year><volume>33</volume><fpage>891</fpage><lpage>905</lpage></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corman</surname><given-names>VM</given-names></name><etal/></person-group><article-title>Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection</article-title><source>Clin. Infect. Dis.</source><year>2016</year><volume>62</volume><fpage>477</fpage><lpage>483</lpage><?supplied-pmid 26565003?><pub-id pub-id-type="pmid">26565003</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cha</surname><given-names>RH</given-names></name><etal/></person-group><article-title>A case report of a Middle East respiratory syndrome survivor with kidney biopsy results</article-title><source>J. Korean Med. Sci.</source><year>2016</year><volume>31</volume><fpage>635</fpage><lpage>640</lpage><?supplied-pmid 27051251?><pub-id pub-id-type="pmid">27051251</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poissy</surname><given-names>J</given-names></name><etal/></person-group><article-title>Kinetics and pattern of viral excretion in biological specimens of two MERS-CoV cases</article-title><source>J. Clin. Virol.</source><year>2014</year><volume>61</volume><fpage>275</fpage><lpage>278</lpage><?supplied-pmid 25073585?><pub-id pub-id-type="pmid">25073585</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bin</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Environmental contamination and viral shedding in MERS patients during MERS-CoV outbreak in South Korea</article-title><source>Clin. Infect. Dis.</source><year>2016</year><volume>62</volume><fpage>755</fpage><lpage>760</lpage><?supplied-pmid 26679623?><pub-id pub-id-type="pmid">26679623</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><etal/></person-group><article-title>Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus</article-title><source>Sci. Adv.</source><year>2017</year><volume>3</volume><fpage>eaao4966</fpage><?supplied-pmid 29152574?><pub-id pub-id-type="pmid">29152574</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N</given-names></name><etal/></person-group><article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>382</volume><fpage>727</fpage><lpage>733</lpage><?supplied-pmid 7092803?><pub-id pub-id-type="pmid">31978945</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>382</volume><fpage>1199</fpage><lpage>1207</lpage><?supplied-pmid 31995857?><pub-id pub-id-type="pmid">31995857</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><etal/></person-group><article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>1061</fpage><lpage>1069</lpage></element-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Xiong, C. L., Jiang, L. F., Chen, Y. &#x00026; Jiang, Q. W. Evolution and variation of 2019-novel coronavirus. Preprint at 10.1101/2020.01.30.926477 (2020).</mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Riou, J. &#x00026; Althaus, C. L. Pattern of early human-to-human transmission of wuhan 2019 novel coronavirus (2019-nCoV). 10.2807/1560-7917.ES.2020.25.4.2000058 (2020).</mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Liu, T. et al. Transmission dynamics of 2019 novel coronavirus (2019-nCoV). Preprint at 10.1101/2020.01.25.919787 (2020).</mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Shen, M. W., Peng, Z. H., Xiao, Y. N. &#x00026; Zhang, L. Modelling the epidemic trend of the 2019 novel coronavirus outbreak in China. Preprint at 10.1101/2020.01.23.916726 (2020).</mixed-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guangdi</surname><given-names>L</given-names></name><name><surname>Erik</surname><given-names>DC</given-names></name></person-group><article-title>Therapeutic options for the 2019 novel coronavirus (2019-nCoV)</article-title><source>Nat. Rev. Drug Discov.</source><year>2020</year><volume>19</volume><fpage>149</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">32127666</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>497</fpage><lpage>506</lpage><?supplied-pmid 7159299?><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>565</fpage><lpage>574</lpage><?supplied-pmid 7159086?><pub-id pub-id-type="pmid">32007145</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>CW</given-names></name><name><surname>Chan</surname><given-names>MH</given-names></name><name><surname>Wong</surname><given-names>CK</given-names></name></person-group><article-title>Severe acute respiratory syndrome: clinical and laboratory manifestations</article-title><source>Clin. Biochem. Rev.</source><year>2004</year><volume>25</volume><fpage>121</fpage><lpage>132</lpage><?supplied-pmid 18458712?><pub-id pub-id-type="pmid">18458712</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oboho</surname><given-names>IK</given-names></name><etal/></person-group><article-title>2014 MERS-CoV outbreak in Jeddah&#x02014;a link to health care facilities</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>372</volume><fpage>846</fpage><lpage>854</lpage><?supplied-pmid 25714162?><pub-id pub-id-type="pmid">25714162</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A</given-names></name><etal/></person-group><article-title>Reducing mortality from 2019-nCoV: host-directed therapies should be an option</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>e35</fpage><lpage>e36</lpage><?supplied-pmid 32035018?><pub-id pub-id-type="pmid">32035018</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>McGoogan</surname><given-names>JM</given-names></name></person-group><article-title>Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72&#x02009;314 cases from the Chinese Center for Disease Control and Prevention</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>1239</fpage><lpage>1242</lpage></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>DSC</given-names></name><name><surname>Zumla</surname><given-names>A</given-names></name></person-group><article-title>Severe acute respiratory syndrome: historical, epidemiologic, and clinical features</article-title><source>Infect. Dis. Clin. N. Am.</source><year>2019</year><volume>33</volume><fpage>869</fpage><lpage>889</lpage></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Korteweg</surname><given-names>C</given-names></name><name><surname>McNutt</surname><given-names>MA</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name></person-group><article-title>Pathogenetic mechanisms of severe acute respiratory syndrome</article-title><source>Virus Res.</source><year>2008</year><volume>133</volume><fpage>4</fpage><lpage>12</lpage><?supplied-pmid 17825937?><pub-id pub-id-type="pmid">17825937</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagata</surname><given-names>N</given-names></name><name><surname>Iwata-Yoshikawa</surname><given-names>N</given-names></name><name><surname>Taguchi</surname><given-names>F</given-names></name></person-group><article-title>Studies of severe acute respiratory syndrome coronavirus pathology in human cases and animal models</article-title><source>Vet. Pathol.</source><year>2010</year><volume>47</volume><fpage>881</fpage><lpage>892</lpage><?supplied-pmid 20664013?><pub-id pub-id-type="pmid">20664013</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The clinical pathology of severe acute respiratory syndrome (SARS): a report from China</article-title><source>J. Pathol.</source><year>2003</year><volume>200</volume><fpage>282</fpage><lpage>289</lpage><?supplied-pmid 12845623?><pub-id pub-id-type="pmid">12845623</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Spatiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques</article-title><source>Mucosal Immunol.</source><year>2016</year><volume>9</volume><fpage>1089</fpage><lpage>1101</lpage><?supplied-pmid 26647718?><pub-id pub-id-type="pmid">26647718</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways</article-title><source>J. Pathol.</source><year>2004</year><volume>203</volume><fpage>622</fpage><lpage>630</lpage><?supplied-pmid 15141376?><pub-id pub-id-type="pmid">15141376</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>X</given-names></name><etal/></person-group><article-title>Severe acute respiratory syndrome associated coronavirus is detected in intestinal tissues of fatal cases</article-title><source>Am. J. Gastroenterol.</source><year>2005</year><volume>100</volume><fpage>169</fpage><lpage>176</lpage><?supplied-pmid 15654797?><pub-id pub-id-type="pmid">15654797</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chau</surname><given-names>TN</given-names></name><etal/></person-group><article-title>SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases</article-title><source>Hepatology</source><year>2004</year><volume>39</volume><fpage>302</fpage><lpage>310</lpage><?supplied-pmid 14767982?><pub-id pub-id-type="pmid">14767982</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haneya</surname><given-names>A</given-names></name><etal/></person-group><article-title>Impact of acute kidney injury on outcome in patients with severe acute respiratory failure receiving extracorporeal membrane oxygenation</article-title><source>Crit. Care Med.</source><year>2015</year><volume>43</volume><fpage>1898</fpage><lpage>1906</lpage><?supplied-pmid 26066017?><pub-id pub-id-type="pmid">26066017</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>KH</given-names></name><etal/></person-group><article-title>Acute renal impairment in coronavirus-associated severe acute respiratory syndrome</article-title><source>Kidney Int.</source><year>2005</year><volume>67</volume><fpage>698</fpage><lpage>705</lpage><?supplied-pmid 15673319?><pub-id pub-id-type="pmid">15673319</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Multiple organ infection and the pathogenesis of SARS</article-title><source>J. Exp. Med.</source><year>2005</year><volume>202</volume><fpage>415</fpage><lpage>424</lpage><?supplied-pmid 16043521?><pub-id pub-id-type="pmid">16043521</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014</article-title><source>Am. J. Pathol.</source><year>2016</year><volume>186</volume><fpage>652</fpage><lpage>658</lpage><?supplied-pmid 26857507?><pub-id pub-id-type="pmid">26857507</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>NS</given-names></name><etal/></person-group><article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>507</fpage><lpage>513</lpage><?supplied-pmid 32007143?><pub-id pub-id-type="pmid">32007143</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="other">Chen, Z. et al. Caution: clinical characteristics of COVID-19 patients are changing at admission. Preprint at 10.1101/2020.03.03.20030833 (2020).</mixed-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Luhur</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>SM</given-names></name></person-group><article-title>Yeast expression and characterization of SARS-CoV N protein</article-title><source>J. Virol. Methods</source><year>2005</year><volume>130</volume><fpage>83</fpage><lpage>88</lpage><?supplied-pmid 16026862?><pub-id pub-id-type="pmid">16026862</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>CK</given-names></name><etal/></person-group><article-title>The SARS coronavirus nucleocapsid protein&#x02014;forms and functions</article-title><source>Antivir. Res.</source><year>2014</year><volume>103</volume><fpage>39</fpage><lpage>50</lpage><?supplied-pmid 24418573?><pub-id pub-id-type="pmid">24418573</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cong</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Nucleocapsid protein recruitment to replication-transcription complexes plays a crucial role in coronaviral life cycle</article-title><source>J. Virol.</source><year>2019</year><pub-id pub-id-type="doi">10.1128/jvi.01925-19</pub-id><?supplied-pmid 31118252?><pub-id pub-id-type="pmid">31118252</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>KV</given-names></name></person-group><article-title>SARS-associated coronavirus</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>348</volume><fpage>1948</fpage><lpage>1951</lpage><?supplied-pmid 12748314?><pub-id pub-id-type="pmid">12748314</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bleibtreu</surname><given-names>A</given-names></name><etal/></person-group><article-title>Focus on Middle East respiratory syndrome coronavirus (MERS-CoV)</article-title><source>M&#x000e9;d. Mal. Infect.</source><year>2020</year><volume>50</volume><fpage>243</fpage><lpage>251</lpage><?supplied-pmid 31727466?><pub-id pub-id-type="pmid">31727466</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YH</given-names></name><etal/></person-group><article-title>Molecular characteristics, functions, and related pathogenicity of MERS-CoV</article-title><source>Proteins Eng.</source><year>2019</year><volume>5</volume><fpage>940</fpage><lpage>947</lpage></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>L</given-names></name></person-group><article-title>Prospects for a MERS-CoV spike vaccine</article-title><source>Expert Rev. Vaccines</source><year>2018</year><volume>17</volume><fpage>677</fpage><lpage>686</lpage><?supplied-pmid 30058403?><pub-id pub-id-type="pmid">30058403</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chafekar</surname><given-names>A</given-names></name><name><surname>Fielding</surname><given-names>BC</given-names></name></person-group><article-title>MERS-CoV: understanding the latest human coronavirus threat</article-title><source>Viruses</source><year>2018</year><volume>10</volume><fpage>93</fpage></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists</article-title><source>Protein Cell</source><year>2013</year><volume>4</volume><fpage>951</fpage><lpage>961</lpage><?supplied-pmid 24318862?><pub-id pub-id-type="pmid">24318862</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thornbrough</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Middle East respiratory syndrome coronavirus NS4b protein inhibits host RNase L activation</article-title><source>mBio</source><year>2016</year><volume>7</volume><fpage>e00258</fpage><?supplied-pmid 27025250?><pub-id pub-id-type="pmid">27025250</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakagawa</surname><given-names>K</given-names></name><etal/></person-group><article-title>The endonucleolytic RNA cleavage function of nsp1 of Middle East respiratory syndrome coronavirus promotes the production of infectious virus particles in specific human cell lines</article-title><source>J. Virol.</source><year>2018</year><volume>92</volume><fpage>e01157-18</fpage><?supplied-pmid 30111568?><pub-id pub-id-type="pmid">30111568</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menachery</surname><given-names>VD</given-names></name><etal/></person-group><article-title>Middle East respiratory syndrome coronavirus nonstructural protein 16 is necessary for interferon resistance and viral pathogenesis</article-title><source>mSphere</source><year>2017</year><volume>2</volume><fpage>00346-17</fpage></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batool</surname><given-names>M</given-names></name><etal/></person-group><article-title>Structural insights into the Middle East respiratory syndrome coronavirus 4a protein and its dsRNA binding mechanism</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>11362</fpage><?supplied-pmid 28900197?><pub-id pub-id-type="pmid">28900197</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>W</given-names></name><etal/></person-group><article-title>Crystal structure of Middle East respiratory syndrome coronavirus helicase</article-title><source>PLoS Pathog.</source><year>2017</year><volume>13</volume><fpage>e1006474</fpage><?supplied-pmid 28651017?><pub-id pub-id-type="pmid">28651017</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>S</given-names></name><etal/></person-group><article-title>Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein</article-title><source>Virus Res.</source><year>2014</year><volume>194</volume><fpage>200</fpage><lpage>210</lpage><?supplied-pmid 25451066?><pub-id pub-id-type="pmid">25451066</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X</given-names></name><etal/></person-group><article-title>Interaction of N-acetyl-seryl-aspartyl-lysyl-proline with the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis attenuates pulmonary fibrosis in silicotic rats</article-title><source>Exp. Physiol.</source><year>2019</year><volume>104</volume><fpage>1562</fpage><lpage>1574</lpage><?supplied-pmid 31290182?><pub-id pub-id-type="pmid">31290182</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>10777</fpage><lpage>10783</lpage><?supplied-pmid 23903833?><pub-id pub-id-type="pmid">23903833</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein</article-title><source>Sci. Transl. Med.</source><year>2014</year><volume>6</volume><fpage>234ra259</fpage></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>G</given-names></name><etal/></person-group><article-title>Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26</article-title><source>Nature</source><year>2013</year><volume>500</volume><fpage>227</fpage><lpage>231</lpage><?supplied-pmid 7095341?><pub-id pub-id-type="pmid">23831647</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kandeel</surname><given-names>M</given-names></name><etal/></person-group><article-title>Association of host tropism of Middle East syndrome coronavirus with the amino acid structure of host cell receptor dipeptidyl peptidase 4</article-title><source>Acta Virol.</source><year>2014</year><volume>58</volume><fpage>359</fpage><lpage>363</lpage><?supplied-pmid 25518718?><pub-id pub-id-type="pmid">25518718</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><mixed-citation publication-type="other">Wu, F. et al. Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China. Preprint at 10.1101/2020.01.24.919183 (2020).</mixed-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P</given-names></name><etal/></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><year>2020</year><volume>579</volume><fpage>270</fpage><lpage>273</lpage><?supplied-pmid 7095418?><pub-id pub-id-type="pmid">32015507</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><mixed-citation publication-type="other">Guo, Q. et al. Host and infectivity prediction of Wuhan 2019 novel coronavirus using deep learning algorithm. Preprint at 10.1101/2020.01.21.914044 (2020).</mixed-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Molecular mechanism of evolution and human infection</article-title><source>Viruses</source><year>2020</year><volume>12</volume><fpage>428</fpage></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F</given-names></name><etal/></person-group><article-title>A new coronavirus associated with human respiratory disease in China</article-title><source>Nature</source><year>2020</year><volume>579</volume><fpage>265</fpage><lpage>269</lpage><?supplied-pmid 32015508?><pub-id pub-id-type="pmid">32015508</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>XT</given-names></name><etal/></person-group><article-title>Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission</article-title><source>Sci. China Life Sci.</source><year>2020</year><volume>63</volume><fpage>457</fpage><lpage>460</lpage><?supplied-pmid 32009228?><pub-id pub-id-type="pmid">32009228</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><mixed-citation publication-type="other">Yan, R. H. et al. Structure of dimeric full-length human ACE2 in complex with B0AT1. Preprint at 10.1101/2020.02.17.951848 (2020).</mixed-citation></ref><ref id="CR82"><label>82.</label><mixed-citation publication-type="other">Wang, K. et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. Preprint at 10.1101/2020.03.14.988345 (2020).</mixed-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamming</surname><given-names>I</given-names></name><etal/></person-group><article-title>The emerging role of ACE2 in physiology and disease</article-title><source>J. Pathol.</source><year>2007</year><volume>212</volume><fpage>1</fpage><lpage>11</lpage><?supplied-pmid 17464936?><pub-id pub-id-type="pmid">17464936</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>K</given-names></name><etal/></person-group><article-title>A virus-binding hot spot on human angiotensin-converting enzyme 2 is critical for binding of two different coronaviruses</article-title><source>J. Virol.</source><year>2011</year><volume>85</volume><fpage>5331</fpage><lpage>5337</lpage><?supplied-pmid 21411533?><pub-id pub-id-type="pmid">21411533</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuba</surname><given-names>K</given-names></name><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Penninger</surname><given-names>JM</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 in lung diseases</article-title><source>Curr. Opin. Pharmacol.</source><year>2006</year><volume>6</volume><fpage>271</fpage><lpage>276</lpage><?supplied-pmid 16581295?><pub-id pub-id-type="pmid">16581295</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemnes</surname><given-names>AR</given-names></name><etal/></person-group><article-title>A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension</article-title><source>Eur. Respir. J.</source><year>2018</year><volume>51</volume><fpage>1702638</fpage><?supplied-pmid 29903860?><pub-id pub-id-type="pmid">29903860</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heurich</surname><given-names>A</given-names></name><etal/></person-group><article-title>TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>1293</fpage><lpage>1307</lpage><?supplied-pmid 24227843?><pub-id pub-id-type="pmid">24227843</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Middle East respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways</article-title><source>J. Infect. Dis.</source><year>2016</year><volume>213</volume><fpage>904</fpage><lpage>914</lpage><?supplied-pmid 26203058?><pub-id pub-id-type="pmid">26203058</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kint</surname><given-names>J</given-names></name><etal/></person-group><article-title>Activation of the chicken type I interferon response by infectious bronchitis coronavirus</article-title><source>J. Virol.</source><year>2015</year><volume>89</volume><fpage>1156</fpage><lpage>1167</lpage><?supplied-pmid 25378498?><pub-id pub-id-type="pmid">25378498</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth Cross</surname><given-names>JK</given-names></name><name><surname>Bender</surname><given-names>SJ</given-names></name><name><surname>Weiss</surname><given-names>SR</given-names></name></person-group><article-title>Murine coronavirus mouse hepatitis virus is recognized by MDA5 and induces type I interferon in brain macrophages/microglia</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>9829</fpage><lpage>9838</lpage><?supplied-pmid 18667505?><pub-id pub-id-type="pmid">18667505</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Ribonuclease L and metal-ion-independent endoribonuclease cleavage sites in host and viral RNAs</article-title><source>Nucleic Acids Res.</source><year>2014</year><volume>42</volume><fpage>5202</fpage><lpage>5216</lpage><?supplied-pmid 24500209?><pub-id pub-id-type="pmid">24500209</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>RH</given-names></name></person-group><article-title>Viral encounters with 2&#x02019;,5&#x02019;-oligoadenylate synthetase and RNase L during the interferon antiviral response</article-title><source>J. Virol.</source><year>2007</year><volume>81</volume><fpage>12720</fpage><lpage>12729</lpage><?supplied-pmid 17804500?><pub-id pub-id-type="pmid">17804500</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Dimeric structure of pseudokinase RNase L bound to 2-5A reveals a basis for interferon-induced antiviral activity</article-title><source>Mol. Cell</source><year>2014</year><volume>53</volume><fpage>221</fpage><lpage>234</lpage><?supplied-pmid 24462203?><pub-id pub-id-type="pmid">24462203</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><etal/></person-group><article-title>Homologous 2&#x02019;,5&#x02019;-phosphodiesterases from disparate RNA viruses antagonize antiviral innate immunity</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2013</year><volume>110</volume><fpage>13114</fpage><lpage>13119</lpage><?supplied-pmid 23878220?><pub-id pub-id-type="pmid">23878220</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niemeyer</surname><given-names>D</given-names></name><etal/></person-group><article-title>Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>12489</fpage><lpage>12495</lpage><?supplied-pmid 24027320?><pub-id pub-id-type="pmid">24027320</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>KL</given-names></name><etal/></person-group><article-title>The ORF4b-encoded accessory proteins of Middle East respiratory syndrome coronavirus and two related bat coronaviruses localize to the nucleus and inhibit innate immune signalling</article-title><source>J. Gen. Virol.</source><year>2014</year><volume>95</volume><fpage>874</fpage><lpage>882</lpage><?supplied-pmid 24443473?><pub-id pub-id-type="pmid">24443473</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JFW</given-names></name><etal/></person-group><article-title>A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>514</fpage><lpage>523</lpage><?supplied-pmid 7159286?><pub-id pub-id-type="pmid">31986261</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>CW</given-names></name><name><surname>Liu</surname><given-names>XF</given-names></name><name><surname>Jia</surname><given-names>ZF</given-names></name></person-group><article-title>2019-nCoV transmission through the ocular surface must not be ignored</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>10224</fpage></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothe</surname><given-names>C</given-names></name><etal/></person-group><article-title>Transmission of 2019-nCoV infection from an asymptomatic contact in Germany</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>382</volume><fpage>970</fpage><lpage>971</lpage><?supplied-pmid 32003551?><pub-id pub-id-type="pmid">32003551</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><etal/></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>271</fpage><lpage>280</lpage><?supplied-pmid 32142651?><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><mixed-citation publication-type="other">Zhao, Y. et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. Preprint at 10.1101/2020.01.26.919985 (2020).</mixed-citation></ref><ref id="CR102"><label>102.</label><mixed-citation publication-type="other">Zhang, H. et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. Preprint at 10.1101/2020.01.30.927806 (2020).</mixed-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>X</given-names></name><etal/></person-group><article-title>The single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to Wuhan 2019-nCoV infection</article-title><source>Front. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s11684-020-0754-0</pub-id><?supplied-pmid 32170560?><pub-id pub-id-type="pmid">32170560</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><mixed-citation publication-type="other">Jia, X. et al. Two things about COVID-19 might need attention. Preprint at 10.20944/preprints202002.0315.v1 (2020).</mixed-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>D</given-names></name><etal/></person-group><article-title>Development and validation of a rapid immunochromatographic assay for detection of Middle East respiratory syndrome coronavirus antigen in dromedary camels</article-title><source>J. Clin. Microbiol.</source><year>2015</year><volume>53</volume><fpage>1178</fpage><lpage>1182</lpage><?supplied-pmid 25631809?><pub-id pub-id-type="pmid">25631809</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peeri</surname><given-names>NC</given-names></name><etal/></person-group><article-title>The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?</article-title><source>Int. J. Epidemiol.</source><year>2020</year><pub-id pub-id-type="doi">10.1093/ije/dyaa033</pub-id><?supplied-pmid 32086938?><pub-id pub-id-type="pmid">32086938</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nassar</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Middle East respiratory syndrome coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics</article-title><source>Eur. Rev. Med. Pharmacol. Sci.</source><year>2018</year><volume>22</volume><fpage>4956</fpage><lpage>4961</lpage><?supplied-pmid 30070331?><pub-id pub-id-type="pmid">30070331</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguanno</surname><given-names>R</given-names></name><etal/></person-group><article-title>MERS: progress on the global response, remaining challenges and the way forward</article-title><source>Antivir. Res.</source><year>2018</year><volume>159</volume><fpage>35</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">30236531</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><mixed-citation publication-type="other">Wang, M. et al. Nanopore target sequencing for accurate and comprehensive detection of SARS-CoV-2 and other respiratory viruses. Preprint at 10.1101/2020.03.04.20029538 (2020).</mixed-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>MERS-CoV spike protein: targets for vaccines and therapeutics</article-title><source>Antivir. Res.</source><year>2016</year><volume>133</volume><fpage>165</fpage><lpage>177</lpage><?supplied-pmid 27468951?><pub-id pub-id-type="pmid">27468951</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>LY</given-names></name><etal/></person-group><article-title>Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>9939</fpage><?supplied-pmid 23824801?><pub-id pub-id-type="pmid">23824801</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyall</surname><given-names>J</given-names></name><etal/></person-group><article-title>Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>4885</fpage><lpage>4893</lpage><?supplied-pmid 24841273?><pub-id pub-id-type="pmid">24841273</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><etal/></person-group><article-title>Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>3068</fpage><?supplied-pmid 31296843?><pub-id pub-id-type="pmid">31296843</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents</article-title><source>Viral Immunol.</source><year>2014</year><volume>27</volume><fpage>543</fpage><lpage>550</lpage><?supplied-pmid 25387086?><pub-id pub-id-type="pmid">25387086</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A</given-names></name><etal/></person-group><article-title>Coronaviruses&#x02014;drug discovery and therapeutic options</article-title><source>Nat. Rev. Drug Discov.</source><year>2016</year><volume>15</volume><fpage>327</fpage><lpage>347</lpage><?supplied-pmid 26868298?><pub-id pub-id-type="pmid">26868298</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><mixed-citation publication-type="other">Bian, H. et al. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. Preprint at 10.1101/2020.03.21.20040691 (2020).</mixed-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title><source>Cell Res.</source><year>2020</year><volume>30</volume><fpage>269</fpage><lpage>271</lpage><?supplied-pmid 32020029?><pub-id pub-id-type="pmid">32020029</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>XT</given-names></name><etal/></person-group><article-title>In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</article-title><source>Clin. Infect. Dis.</source><year>2020</year><pub-id pub-id-type="doi">10.1093/cid/ciaa237</pub-id><?supplied-pmid 32161968?><pub-id pub-id-type="pmid">32161968</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautret</surname><given-names>P</given-names></name><etal/></person-group><article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</article-title><source>Int. J. Antimicrob. Agents.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105949</pub-id><?supplied-pmid 32205204?><pub-id pub-id-type="pmid">32205204</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>L</given-names></name><etal/></person-group><article-title>Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study</article-title><source>J. Inf. Secur.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jinf.2020.03.002</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>KW</given-names></name><etal/></person-group><article-title>Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus</article-title><source>Antivir. Res.</source><year>2015</year><volume>115</volume><fpage>9</fpage><lpage>16</lpage><?supplied-pmid 25542975?><pub-id pub-id-type="pmid">25542975</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loutfy</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study</article-title><source>JAMA</source><year>2003</year><volume>290</volume><fpage>3222</fpage><lpage>3228</lpage><?supplied-pmid 14693875?><pub-id pub-id-type="pmid">14693875</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>XJ</given-names></name></person-group><article-title>Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines</article-title><source>J. Genet. Genom.</source><year>2020</year><volume>47</volume><fpage>119</fpage><lpage>121</lpage></element-citation></ref><ref id="CR124"><label>124.</label><mixed-citation publication-type="other">Chenghao, Y. et al. Theoretical study of the anti-ncp molecular mechanism of traditional chinese medicine lianhua-qingwen formula (LQF). (2020).</mixed-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>TP</given-names></name><etal/></person-group><article-title>Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses</article-title><source>Sci. Transl. Med.</source><year>2017</year><volume>9</volume><fpage>eaal3653</fpage><?supplied-pmid 28659436?><pub-id pub-id-type="pmid">28659436</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holshue</surname><given-names>ML</given-names></name><etal/></person-group><article-title>First case of 2019 novel coronavirus in the United States</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>382</volume><fpage>929</fpage><lpage>936</lpage><?supplied-pmid 32004427?><pub-id pub-id-type="pmid">32004427</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>So</surname><given-names>LK</given-names></name><etal/></person-group><article-title>Development of a standard treatment protocol for severe acute respiratory syndrome</article-title><source>Lancet</source><year>2003</year><volume>361</volume><fpage>1615</fpage><lpage>1617</lpage><?supplied-pmid 12747883?><pub-id pub-id-type="pmid">12747883</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>YM</given-names></name><etal/></person-group><article-title>Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2018</year><volume>197</volume><fpage>757</fpage><lpage>767</lpage><?supplied-pmid 29161116?><pub-id pub-id-type="pmid">29161116</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>CD</given-names></name><name><surname>Millar</surname><given-names>JE</given-names></name><name><surname>Baillie</surname><given-names>JK</given-names></name></person-group><article-title>Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>473</fpage><lpage>475</lpage><?supplied-pmid 32043983?><pub-id pub-id-type="pmid">32043983</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soo</surname><given-names>YO</given-names></name><etal/></person-group><article-title>Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients</article-title><source>Clin. Microbiol. Infect.</source><year>2004</year><volume>10</volume><fpage>676</fpage><lpage>678</lpage><?supplied-pmid 15214887?><pub-id pub-id-type="pmid">15214887</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><mixed-citation publication-type="other">Zhou, Y. et al. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. Preprint at 10.1101/2020.02.12.945576 (2020).</mixed-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goo</surname><given-names>J</given-names></name><etal/></person-group><article-title>Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein</article-title><source>Virus Res.</source><year>2020</year><volume>278</volume><fpage>197863</fpage><?supplied-pmid 31945421?><pub-id pub-id-type="pmid">31945421</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Discovery of hydrocarbon-stapled short &#x003b1;-helical peptides as promising Middle East respiratory syndrome coronavirus (MERS-CoV) fusion inhibitors</article-title><source>J. Med. Chem.</source><year>2018</year><volume>61</volume><fpage>2018</fpage><lpage>2026</lpage><?supplied-pmid 29442512?><pub-id pub-id-type="pmid">29442512</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Momattin</surname><given-names>H</given-names></name><name><surname>Al Ali</surname><given-names>AY</given-names></name><name><surname>Al-Tawfiq</surname><given-names>JA</given-names></name></person-group><article-title>A systematic review of therapeutic agents for the treatment of the Middle East respiratory syndrome coronavirus (MERS-CoV)</article-title><source>Travel Med. Infect. Dis.</source><year>2019</year><volume>30</volume><fpage>9</fpage><lpage>18</lpage><?supplied-pmid 31252170?><pub-id pub-id-type="pmid">31252170</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elshabrawy</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>4353</fpage><lpage>4365</lpage><?supplied-pmid 24501399?><pub-id pub-id-type="pmid">24501399</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mustafa</surname><given-names>S</given-names></name><name><surname>Balkhy</surname><given-names>H</given-names></name><name><surname>Gabere</surname><given-names>MN</given-names></name></person-group><article-title>Current treatment options and the role of peptides as potential therapeutic components for Middle East respiratory syndrome (MERS): a review</article-title><source>J. Infect. Public Health</source><year>2018</year><volume>11</volume><fpage>9</fpage><lpage>17</lpage><?supplied-pmid 28864360?><pub-id pub-id-type="pmid">28864360</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horie</surname><given-names>S</given-names></name><name><surname>Gonzalez</surname><given-names>HE</given-names></name><name><surname>Laffey</surname><given-names>JG</given-names></name><name><surname>Masterson</surname><given-names>CH</given-names></name></person-group><article-title>Cell therapy in acute respiratory distress syndrome</article-title><source>J. Thorac. Dis.</source><year>2018</year><volume>10</volume><fpage>5607</fpage><lpage>5620</lpage><?supplied-pmid 30416812?><pub-id pub-id-type="pmid">30416812</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>SH</given-names></name><name><surname>McElrath</surname><given-names>MJ</given-names></name><name><surname>Lewis</surname><given-names>DJ</given-names></name><name><surname>Del Giudice</surname><given-names>G</given-names></name></person-group><article-title>Challenges and responses in human vaccine development</article-title><source>Curr. Opin. Immunol.</source><year>2014</year><volume>28</volume><fpage>18</fpage><lpage>26</lpage><?supplied-pmid 24561742?><pub-id pub-id-type="pmid">24561742</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2004</year><volume>324</volume><fpage>773</fpage><lpage>781</lpage><?supplied-pmid 15474494?><pub-id pub-id-type="pmid">15474494</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>BM</given-names></name><name><surname>Kang</surname><given-names>TJ</given-names></name></person-group><article-title>Expression of B subunit of <italic>E. coli</italic> heat-labile enterotoxin in the progenies of transgenic tobacco bred by crossing nuclear- and chloroplast-transgenic lines</article-title><source>Protein Expr. Purif.</source><year>2019</year><volume>155</volume><fpage>54</fpage><lpage>58</lpage><?supplied-pmid 30468854?><pub-id pub-id-type="pmid">30468854</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E</given-names></name><etal/></person-group><article-title>Immunogenicity of an adenoviral-based Middle East respiratory syndrome coronavirus vaccine in BALB/c mice</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>5975</fpage><lpage>5982</lpage><?supplied-pmid 25192975?><pub-id pub-id-type="pmid">25192975</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wirblich</surname><given-names>C</given-names></name><etal/></person-group><article-title>One-Health: a safe, efficient, dual-use vaccine for humans and animals against Middle East respiratory syndrome coronavirus and rabies virus</article-title><source>J. Virol.</source><year>2017</year><volume>91</volume><fpage>e02040-16</fpage><?supplied-pmid 27807241?><pub-id pub-id-type="pmid">27807241</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><year>2020</year><volume>367</volume><fpage>1260</fpage><lpage>1263</lpage><?supplied-pmid 32075877?><pub-id pub-id-type="pmid">32075877</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>P</given-names></name><etal/></person-group><article-title>DNA vaccine of SARS-Cov S gene induces antibody response in mice</article-title><source>Acta Biochim. Biophys. Sin.</source><year>2004</year><volume>36</volume><fpage>37</fpage><lpage>41</lpage><?supplied-pmid 14732873?><pub-id pub-id-type="pmid">14732873</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alharbi</surname><given-names>NK</given-names></name><etal/></person-group><article-title>ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>3780</fpage><lpage>3788</lpage><?supplied-pmid 28579232?><pub-id pub-id-type="pmid">28579232</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haagmans</surname><given-names>BL</given-names></name><etal/></person-group><article-title>An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels</article-title><source>Science</source><year>2016</year><volume>351</volume><fpage>77</fpage><lpage>81</lpage><?supplied-pmid 26678878?><pub-id pub-id-type="pmid">26678878</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>C</given-names></name><etal/></person-group><article-title>Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments&#x02014;the importance of immunofocusing in subunit vaccine design</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>6170</fpage><lpage>6176</lpage><?supplied-pmid 25240756?><pub-id pub-id-type="pmid">25240756</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>VS</given-names></name><etal/></person-group><article-title>Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>1834</fpage><lpage>1838</lpage><?supplied-pmid 24257613?><pub-id pub-id-type="pmid">24257613</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohnuma</surname><given-names>K</given-names></name><etal/></person-group><article-title>Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>13892</fpage><?supplied-pmid 24067970?><pub-id pub-id-type="pmid">24067970</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Rao</surname><given-names>X</given-names></name><name><surname>Rajagopalan</surname><given-names>S</given-names></name></person-group><article-title>An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease</article-title><source>Atherosclerosis</source><year>2013</year><volume>226</volume><fpage>305</fpage><lpage>314</lpage><?supplied-pmid 23083681?><pub-id pub-id-type="pmid">23083681</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><mixed-citation publication-type="other">Jaimes, J. A., Andr&#x000e9;, N. M., Millet, J. K. &#x00026; Whittaker, G. Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses. Preprint at 10.1101/2020.02.10.942185 (2020).</mixed-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>TP</given-names></name><etal/></person-group><article-title>Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>222</fpage><?supplied-pmid 31924756?><pub-id pub-id-type="pmid">31924756</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Disulfiram can inhibit MERS and SARS coronaviruspapain-like proteases via different modes</article-title><source>Antiviral Res.</source><year>2018</year><volume>150</volume><fpage>155</fpage><lpage>163</lpage><?supplied-pmid 29289665?><pub-id pub-id-type="pmid">29289665</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><etal/></person-group><article-title>De novo design of &#x003b1;-helical lipopeptides targeting viral fusion proteins: a promising strategy for relatively broad-spectrum antiviral drug discovery</article-title><source>J. Med. Chem.</source><year>2018</year><volume>61</volume><fpage>8734</fpage><lpage>8745</lpage><?supplied-pmid 30192544?><pub-id pub-id-type="pmid">30192544</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>3067</fpage><?supplied-pmid 24473083?><pub-id pub-id-type="pmid">24473083</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauch</surname><given-names>S</given-names></name><name><surname>Jasny</surname><given-names>E</given-names></name><name><surname>Schmidt</surname><given-names>KE</given-names></name><name><surname>Petsch</surname><given-names>B</given-names></name></person-group><article-title>New vaccine technologies to combat outbreak situations</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>1963</fpage><?supplied-pmid 30283434?><pub-id pub-id-type="pmid">30283434</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modjarrad</surname><given-names>K</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial</article-title><source>Lancet Infect. Dis.</source><year>2019</year><volume>19</volume><fpage>1013</fpage><lpage>1022</lpage><?supplied-pmid 31351922?><pub-id pub-id-type="pmid">31351922</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>ZY</given-names></name><etal/></person-group><article-title>A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice</article-title><source>Nature</source><year>2004</year><volume>428</volume><fpage>561</fpage><lpage>564</lpage><?supplied-pmid 15024391?><pub-id pub-id-type="pmid">15024391</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>JE</given-names></name><etal/></person-group><article-title>A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>6338</fpage><lpage>6343</lpage><?supplied-pmid 18824060?><pub-id pub-id-type="pmid">18824060</pub-id></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>X</given-names></name><etal/></person-group><article-title>Potent binding of 2019 novelcoronavirus spike protein by a SARS coronavirus-specific human monoclonalantibody</article-title><source>Emerg. Microbes. Infect.</source><year>2020</year><volume>9</volume><fpage>382</fpage><lpage>385</lpage><?supplied-pmid 32065055?><pub-id pub-id-type="pmid">32065055</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sui</surname><given-names>J</given-names></name><etal/></person-group><article-title>Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association</article-title><source>Proc. Natl Acad. Sci. USA.</source><year>2004</year><volume>101</volume><fpage>2536</fpage><lpage>2541</lpage><?supplied-pmid 14983044?><pub-id pub-id-type="pmid">14983044</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies</article-title><source>Proc. Natl Acad. Sci. USA.</source><year>2007</year><volume>104</volume><fpage>12123</fpage><lpage>12128</lpage><?supplied-pmid 17620608?><pub-id pub-id-type="pmid">17620608</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ying</surname><given-names>T</given-names></name><etal/></person-group><article-title>Exceptionally potent neutralizationof Middle East respiratory syndrome coronavirus by human monoclonalantibodies</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>7796</fpage><lpage>7805</lpage><?supplied-pmid 24789777?><pub-id pub-id-type="pmid">24789777</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Interaction between heptad repeat 1 and 2 regions inspike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors</article-title><source>Lancet</source><year>2004</year><volume>363</volume><fpage>938</fpage><lpage>947</lpage><?supplied-pmid 15043961?><pub-id pub-id-type="pmid">15043961</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><mixed-citation publication-type="other">Xia, S. et al. Fusion mechanism of 2019-nCoV andfusion inhibitors targeting HR1 domain in spike protein. <italic>Cell Mol. Immunol</italic>. (2020).</mixed-citation></ref></ref-list></back></article>